Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2015
  • Online publication date: April 2015

Section 1 - Ambulatory office practice

References

1. PanelNC. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785–795.
2. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation.
3. National Osteoporosis Foundation. Consensus Development Conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646–650.
4. BurgeR, Dawson-HughesB, SolomonDH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:465–475.
5. JohnellO, KanisJA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726–1733.
6. LeslieWD, O'DonnellS, JeanS, et al. Trends in hip fracture rates in Canada. JAMA 2009;302:883–889.
7. MeltonLJ, III, KearnsAE, AtkinsonEJ, et al. Secular trends in hip fracture incidence and recurrence. Osteoporos Int 2009;20:687–694.
8. GehlbachSH, AvruninJS, PuleoE. Trends in hospital care for hip fractures. Osteoporos Int 2007;18:585–591.
9. GehlbachSH, BigelowC, HeimisdottirM, et al. Recognition of vertebral fracture in a clinical setting. Osteoporos Int 2000;11:577–582.
10. International Osteoporosis Foundation. Vertebral Fracture Initiative. Nyon, Switzerland: International Osteoporosis Foundation, 2010.
11. CummingsSR, MeltonLJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761–1767.
12. RalstonSH, UitterlindenAG. Genetics of osteoporosis. Endocr Rev 2010;31:629–662.
13. BaimS, BinkleyN, BilezikianJP, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008;11:75–91.
14. FaulknerKG, von StettenE, MillerP. Discordance in patient classification using T-scores. J Clin Densitom 1999;2:343–350.
15. CummingsSR, BatesD, BlackDM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889–1897.
16. RossPD, DavisJW, VogelJM, WasnichRD. A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tissue Int 1990;46:149–161.
17. US Preventive Services Task Force. Screening for osteoporosis. Ann Intern Med 2011;154:356–364.
18. HillierTA, CauleyJA, RizzoJH, et al. WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis?J Bone Miner Res 2011;26:1774–1782.
19. BlackDM, ArdenNK, PalermoL, PearsonJ, CummingsSR. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14:821–828.
20. MeltonLJ, III, AtkinsonEJ, CooperC, O'FallonWM, RiggsBL. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999;10:214–221.
21. Lewieck, EM, LasterAJ. Clinical review: clinical applications of vertebral fracture assessment by dual-energy X-ray absorptiometry. J Clin Endocrinol Metab 2006;91:4215–4222.
22. BrownJP, AlbertC, NassarBA, et al. Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem 2009;42:929–942.
23. JohnellO, OdenA, De LaetC, et al. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 2002;13:523–526.
24. ReginsterJY, ColletteJ, NeuprezA, et al. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 2008;42:832–836.
25. PainterSE, KleerekoperM, CamachoPM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract 2006;12:436–445.
26. TannenbaumC, ClarkJ, SchwartzmanK, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002;87:4431–4437.
27. KaunitzAM, AriasR, McClungM. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 2008;77:67–76.
28. WalshJS, EastellR, PeelNF. Effects of depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case–control study. J Clin Endocrinol Metab 2008;93:1317–1323.
29. VokesT, FavusM. Clinical management of the patient with osteoporosis. In RobertsonP (ed.) Translational Endocrinology and Metabolism. Chevy Chase, MD: The Endocrine Society, 2010, pp. 9–54.
30. RossAC, MansonJE, AbramsSA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53–58.
31. Martyn-St JamesM, CarrollS. High-intensity resistance training and postmenopausal bone loss: a meta-analysis. Osteoporos Int 2006;17:1225–1240.
32. MoayyeriA. The association between physical activity and osteoporotic fractures: a review of the evidence and implications for future research. Ann Epidemiol 2008;18:827–835.
33. BlackDM, DelmasPD, EastellR, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–1822.
34. KhoslaS, BurrD, CauleyJ, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479–1491.
35. ShaneE, BurrD, EbelingPR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267–2294.
36. BlackDM, SchwartzAV, EnsrudKE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927–2938.
37. SchwartzAV, BauerDC, CummingsSR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010;25:976–982.
38. Writing Group for the PEPI trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389–1396.
39. RossouwJE, AndersonGL, PrenticeRL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
40. Barrett-ConnorE, MoscaL, CollinsP, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125–137.
41. EttingerB, BlackDM, MitlakBH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–645.
42. ReginsterJY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 2011;71:65–78.
43. CummingsSR, EttingerB, DelmasPD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697–708.
44. CummingsSR, EnsrudK, DelmasPD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686–696.
45. CummingsSR, San MartinJ, McClungMR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–765.
46. NeerRM, ArnaudCD, ZanchettaJR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–1441.
47. KhoslaS. Parathyroid hormone plus alendronate: a combination that does not add up. N Engl J Med 2003;349:1277–1279.
48. CosmanF, EriksenEF, RecknorC, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide (rhPTH[1–34]) in postmenopausal osteoporosis. J Bone Miner Res 2011;26:503–511.
49. DealC, OmizoM, SchwartzEN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005;20:1905–1911.
50. KovacsCS, Fuleihan GelH. Calcium and bone disorders during pregnancy and lactation. Endocrinol Metab Clin North Am 2006;35:21–51.
51. RachnerTD, KhoslaS, HofbauerLC. Osteoporosis: now and the future. Lancet 2011;377:1276–1287.

References

1. JohnsonSR. Premenstrual syndrome. In WallisLA (ed.) Textbook of Women's Health. Philadelphia, PA: Lippincott-Raven, 1998, pp. 691–697.
2. ShahNR, JonesJB, AperiJ, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: A meta-analysis. Obstet Gynecol 2008;111:1175–1182.
3. RobinsonGE, StewartDF. Psychological aspects of premenstrual syndrome. In WallisLA (ed.) Textbook of Women's Health. Philadelphia, PA: Lippincott-Raven, 1998, pp. 699–701.
4. DaltonK. The Premenstrual Syndrome and Progesterone Therapy, 2nd edn. Chicago, IL: Mosby Year Book, 1984.
5. American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 15: Premenstrual Syndrome. Washington, DC: American Congress of Obstetricians and Gynecologists, 2000.
6. CunninghamJ, YonkersKA, O'BrienS, et al. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry 2009;17:120–137.
7. RapkinAJ, EdelmuthE, ChangLC, et al. Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol 1987;70:533–537.
8. TaylorDL, MathewRJ, HoBT, et al. Serotonin levels and platelet uptake during premenstrual tension. Neuropsychobiology 1984;12:16–18.
9. RasgonN, SerraM, BiggioG, et al. Neuroactive steroid-serotonergic interaction: responses to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Eur J Endocrinol 2001;145:25–33.
10. MitwallyMF, KahnLS, HalbreichU. Pharmacotherapy of premenstrual syndromes and premenstrual dysphoric disorder: current practices. Expert Opin Pharmacother 2002;3:1577–1590.
11. RocaCA, SchmidtPJ, BlochM, et al. Implications of endocrine studies of premenstrual syndrome. Psychiatr Ann 1996;26:576–580.
12. De BardisD, SerroniN, SalernoRM, et al. Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol. Ther Clin Risk Manag 2007;3:585–590.
13. FreemanEW, FryeCA, RickelsK, et al. Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. J Clin Psychopharmacol 2002;22:516–520.
14. FreemanEW, SondheimerSJ. Premenstrual dysphoric disorder: recognition and treatment. J Clin Psychiatry 2003;5:30–39.
15. SundstromI, NybergS, BackstromT. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 1997;17:370–381.
16. ErikssonE, SundbladC, LandenM, et al. Behavioral effects of androgens in women. In SteinerM, YonkersKA, ErickssonE (eds.) Mood Disorders in Women. London: Martin Dunitz, 2000, pp. 233–246.
17. SteinerM, DunnEJ, MacDougallM, et al. Serotonin transporter gene polymorphism, free testosterone, and symptoms associated with premenstrual dysphoric disorder. Biol Psychiatry 2002;51:91S.
18. HalbreichU, BergeronR, YonkersKA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. In 39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December, 2000.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. Washington, DC: American Psychiatric Association, 2000.
20. HartWG, ColemanGJ, RussellJW. Assessment of premenstrual symptomatology: a re-evaluation of the predictive validity of self-report. J Psychosom Res 1987;31:185–190.
21. Thys-Jacobs, A, FratarcangeloP. Comparative analysis of three PMS assessment: the identification of premenstrual syndrome with core symptoms. Psychopharmacol Bull 1995;31:389–396.
22. SmithMJ, SchmidtPJ, RubinowDR. Operationalizing DSM-IV criteria for PMDD: selecting symptomatic and asymptomatic cycles for research. J Psychiatr Res 2003;37:75–83.
23. O'BrienMS, BackstromT, BrownC, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal Consensus. Arch Womens Ment Health 2011;14:13–21.
24. EndicottJ. The menstrual cycle and mood disorders. J Affect Disord 1993;29:193–200.
25. FrackiewiczEJ, ShiovitzTM. Evaluation and management of premenstrual syndrome and premenstrual dysphoric disorder. J Am Pharm Assoc 2001;41:437–447.
26. SteinerM, PearlsteinT, CohenLS, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: The role of SSRIs. J Women's Health 2006;15:57–69.
27. SundstromI, BackstromT. Patients with premenstrual syndrome have decreased saccadic eye velocity compared to control subjects. Biol Psychiatry 1998;44:755–764.
28. MorseG. Positively reframing perceptions of the menstrual cycle among women with premenstrual syndrome. J Obstet Gynecol Neonatal Nurs 1999;28:165–174.
29. TaylorD. Effectiveness of professional-peer group treatment: symptom management for women with PMS. Res Nurs Health 1999;22:496–511.
30. JohnsonSR. Premenstrual syndrome therapy. Clin Obstet Gynecol 1998;41:405–421.
31. BlumenthalM, BusseWR, GoldbergA, et al. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Austin, TX: American Botanical Council, 1998, p. 1694.
32. GhanbariZ, HaghollahiF, ShariatM, et al. Effects of calcium supplement therapy in women with premenstrual syndrome. Taiwan J Obstet Gynecol 2009;48:124–129.
33. DittmarG, BohnertK. Premenstrual syndrome: treatment with phytopharmaceutical. TW Gynakol 1992;5:60–68.
34. WilliamsJW, MulrowCD, ChiquetteE, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000;132:743–756.
35. SheltonRC, KellerMB, GelenbergA, et al. Effectiveness of St. John's wort in major depression: a randomized placebo controlled trial. JAMA 2001;285:1978–1986.
36. BaylesB, UsatineR, Evening primrose oil. Am Fam Physician 2009;80:1405–1408.
37. HorribinDF, MankuMS, BrushM, et al. Abnormalities in plasma essential fatty acid levels in women with premenstrual syndrome and nonmalignant breast disease. J Nutr Med 1991;2:259–264.
38. DimmockPW, WyattKM, JonesPW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000;356:1131–1136.
39. SteinerM, RavindranAV, LeMelledoJM, et al. Luteal phase administration of paroxetine in the treatment of premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled trial in Canadian women. J Clin Psychiatry 2008;69:991–998.
40. ErikssonE, EkmanA, SinclairS, et al. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 2008;28:195–202.
41. WellsBG, MandosLA, HayesPE. Depressive disorders. In DipiroJT, TalbertRL, YeeGC, et al. (eds.) Pharmacotherapy: A Pathophysiologic Approach. Stamford, CO: Appleton & Lange, 1999, pp. 1141–1160.
42. ClaytonAH, PradkoJF, CroftHA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357–366.
43. FreemanEW, JabaraS, SondheimerSF, et al. Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. J Womens Health Gend Based Med 2002;11:459–464.
44. RothschildAJ. Sexual side effects of antidepressants. J Clin Psychiatry 2000;61:28–36.
45. ErikssonE. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int Clin Psychopharmacol 1999;14(Suppl 2):S27–S33.
46. PearlsteinT, GillespieJA. When should premenstrual dosing in PMDD end? In 155th Annual APA American Psychiatric Association Meeting, Philadelphia, 2002.
47. GoldsteinBJ, GoodnickPJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders. 3. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998;12(Suppl B):S55–S87.
48. FreemanEW, RickelsK, SammelMD, et al. Time to relapse after short- or long-term treatment of severe premenstrual syndrome with sertraline. Arch Gen Psychiatry 2009;66:537–544.
49. SieSD, WenninkJMB, van DrielJJ, et al. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed 2012;97:F472.
50. NulmanI, RovetJ, StewartDE, et al. Neurodevelopment of children exposed in vitro to antidepressant drugs. N Engl J Med 1997;336:258–262.
51. HendrickV, FukuchiA, AltshulerL, et al. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001;179:163–166.
52. HarveyAT, PreskornSH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Pt 11. J Clin Psychopharmacol 1996;6:273–285.
53. HarveyAT, PreskornSH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Pt 11. J Clin Psychopharmacol 1996;16:345–355.
54. KornsteinS, PearlsteinT, FarfelG, et al. Efficacy of sertraline in the treatment of premenstrual syndrome. In 41st Annual Meeting of the New Clinical Drug Evaluation Unit, Phoenix, May, 2001.
55. FreemanEW, RickelsK, ArredondoF, et al. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic anti-depressant. J Clin Psychopharmacol 1999;19:3–8.
56. MazzaM, HarnicD, CatalanoV, et al. Duloxetine for premenstrual dysphoric disorder: a pilot study. Expert Opin Pharmacother 2008;9:517–521.
57. RamosMG, HaraC, RochaFL. Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial. Int J Neuropsychopharmacol 2009;12:1081–1088.
58. FuhrmannU, KrattenmacherR, SlaterEP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243–251.
59. LopezLM, KapteinA, HelmerhorstFM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012;(2):CD006586.
60. MarrJ, NiknianM, ShulmanLP, et al. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen. Contraception 2011;84:81–86.
61. MortolaJF. Applications of gonadotropin-releasing hormone analogues in the treatment of premenstrual syndrome. Clin Obstet Gynecol 1993;36:753–763.
62. RickelsK, FreemanEW. Prior benzodiazepine exposure and benzodiazepine treatment outcome. J Clin Psychiatry 2000;61:409–413.
63. GunstonKD. Premenstrual syndrome in Cape Town. 2. A double-blind placebo-controlled study of the efficacy of mefenamic acid. S Afr Med J 1986;70:159–160.
64. JakubowiczDL, GodardE, DewhurstJ. The treatment of premenstrual tension with mefenamic acid: analysis of prostaglandin concentrations. Br J Obstet Gynaecol 1984;91:78–84.
65. ReesMCP, RandleJ, YudkinP. Mefenamic acid and the premenstrual syndrome. J Obstet Gynaecol 1991;11:359–360.
66. BurnetRB, RaddenHS, EasterbrookEG, et al. Premenstrual syndrome and spironolactone. Aust N Z J Obstet Gynaecol 1991;31:366–368.
67. HellbergD, ClaessonB, NilssonS. Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate. Int J Gynecol Obstet 1991;34:243–248.
68. InoueY, TeraoT, IwataN, et al. Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests. Psychopharmacology 2007;190:213–219.

References

1. United Nations Department of Economic and Social Affairs Population Division DUN. World Population Ageing: 1950–2050. New York: United Nations 2001 (http://www.un.org/esa/population/publications/worldageing19502050/pdf/preface_web.pdf, accessed February 12 2014).
2. CracknellR. Research Key Issues for the New Parliament 2010: The Ageing Population 2010. London: House of Commons.
3. LoboRA. Menopause: endocrinology, consequences of estrogen deficiency, effects of hormone replacement therapy, treatment regimens. In KatzVL, LentzGM, LoboRA, GershensonDM (eds.) Comprehensive Gynecology, 5th edn. Philadelphia, PA: Mosby Elsevier, 2007, Ch. 42.
4. CardozoL, LoseG, McClishD, VersiE, de KoningGH. A systematic review of estrogens for recurrent urinary tract infections: third report of the Hormones and Urogenital Therapy (HUT) Committee. Int Urogynecol J Pelvic Floor Dysfunct 2001;12:15–20.
5. WrightTC, FerenczyA, KurmanRJ. Carcinoma and other tumours of the cervix. In KurmanRJ (ed). Blaustein's Pathology of the Female Genital Tract 4th edn. New York: Springer Verlag, 1994, pp. 279–326.
6. SasieniP, AdamsJ, CuzickJ. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003;89:88–93.
7. PiccoliRMVDLG. Atypical squamous cells and low squamous intraepithelial lesions in postmenopausal women: Implications for management. Eur J Obstet Gynaecol Reprod Biol 2008;140:269–274.
8. MossS, GrayA, LegoodR, et al. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ 2006;332:83–85.
9. WoolfSH. The 2009 Breast Cancer Screening Recommendations of the US Preventive Services Task Force. JAMA 2011;303:162–163.
10. RodstromK, BengtssonC, LissnerL, et al. Longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause 2002;9:156–161.
11. LethabyAE, BrownJ, MarjoribanksJ, et al. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007;(4):CD001395.
12. DavisSR, MoreauM, KrollR, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359:2005–2017.
13. Million Women's Study Collaborators. Breast cancer and HRT in the Million Women's Study. Lancet 2003;362:419–427.
14. ShapiroS, FarmerRD, MueckAO, SeamanH, StevensonJC. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 3. The Women's Health Initiative: unopposed estrogen. J Fam Plann Reprod Health Care 2011;37:225–230.
15. GrodsteinF, MansonJE, StampferMJ, RexrodeK. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861–866.
16. ShumakerSA, LegaultC, RappSR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651–2662.
17. ReckerRR, DaviesKM, DowdRM, HeaneyRP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med 1999;130:897–904.
18. National Osteoporosis Society Guideline Group. Guideline for the Diagnosis and Management of Osteoporosis in Postmenopausal Women and Men from the age of 50 Years in the UK, 2013. Sheffield, UK: National Osteoporosis Society Guideline Group, 2010 (http://www.shef.ac.uk/NOGG/NOGG_Pocket_Guide_for_Healthcare_Professionals.pdf2010, updated 2013, accessed 12 February 2014).
19. IbeC, SimonJA. Vulvovaginal atrophy: current and future therapies (CME). J Sex Med 2010;7:1042–1050.
20. CruickshankME, I Hay. Green-top Guideline 58. The Management of Vulval Skin Disorders. London: Royal College of Obstetricians and Gynaecologists, 2011.
21. Renaud-VilmerC, Cavelier-BalloyB, PorcherR, DubertretL. Vulvar lichen sclerosus: effect of long-term topical application of a potent steroid on the course of the disease. Arch Dermatol 2004;140:709–712.
22. EdwardsCL, BalatO. Characteristics of patients with vulvar cancer: an analysis of 94 patients. Eur J Gynaecol Oncol 1996;17:351–353.
23. JepsonRG, CraigJC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2008;(1):CD001321.
24. BuhrGT, GenaoL, WhiteHK. Urinary tract infections in long-term care residents. Clin Geriatr Med 2011;27:229–239.
25. MelvilleJL, KatonW, DelaneyK, NewtonK. Urinary incontinence in US women: a population-based study. Arch Intern Med 2005;165:537–542.
26. RaoSS, GoJT. Update on the management of constipation in the elderly: new treatment options. Clin Interv Aging 2010;5:163–171.
27. BretschneiderJG, McCoyNL. Sexual interest and behavior in healthy 80- to 102-year-olds. Arch Sex Behav 1988;17:109–129.
28. MastersWH, JohnsonVE. Human Sexual Response. Boston, MA: Little Brown, 1966.
29. BarberMD, ViscoAG, WymanJF, FantlJA, BumpRC. Sexual function in women with urinary incontinence and pelvic organ prolapse. Obstet Gynecol 2002;99:281–289.
30. Statistical Information Team, Cancer Research UK. All Cancers Combined Key Facts. London: Cancer Research UK, 2011 (http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/Allcancerscombined/, accessed 10 December 2013).
31. TimmermansA, OpmeerBC, KhanKS, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 2010;116:160–167.
32. Costa-PaivaL, GodoyCE, Jr., AntunesA, Jr., et al. Risk of malignancy in endometrial polyps in premenopausal and postmenopausal women according to clinicopathologic characteristics. Menopause 2011;18:1278–1282.
33. Barrena MedelNI, HerzogTJ, DeutschI, et al. Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer. Am J Obstet Gynecol 2011;204:248.
34. WrightJD, LewinSN, Barrena MedelNI, et al. Endometrial cancer in the oldest old: Tumor characteristics, patterns of care, and outcome. Gynecol Oncol 2011;122:69–74.
35. RuffordBD, JacobsIJ. Green Top Guideline. Ovarian Cysts in Postmenopausal Women. London: Royal College of Obstetricians and Gynaecologists, 2003.
36. AudisioRA, PopeD, RameshHS, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 2008;65:156–163.
37. MacLennanAH, TaylorAW, WilsonDH, WilsonD. The prevalence of pelvic floor disorders and their relationship to gender, age, parity and mode of delivery. Br J Obstet Gynaecol 2000;107:1460–1470.
38. SungVW, WeitzenS, SokolER, RardinCR, MyersDL. Effect of patient age on increasing morbidity and mortality following urogynecologic surgery. Am J Obstet Gynecol 2006;194:1411–1417.
39. NieminenK, HeinonenPK. Sacrospinous ligament fixation for massive genital prolapse in women aged over 80 years. Br J Obstet Gynaecol 2001;108:817–821.
40. TurrentineFE, WangH, SimpsonVB, JonesRS. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg 2006;203:865–877.

References

1. ZondervanK, BarlowDH. Epidemiology of chronic pelvic pain. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:403–414.
2. LippmanSA, WarnerM, SamuelsS, et al. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril 2003;80:1488–1494.
3. MathiasSD, KuppermannM, LibermanRF, LipschutzRC, SteegeJF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol 1996;87:321–327.
4. HillisSD, MarchbanksPA, PetersonHB. The effectiveness of hysterectomy for chronic pelvic pain. Obstet Gynecol 1995;86:941–945.
5. HowardFM. The role of laparoscopy in chronic pelvic pain: promise and pitfalls. Obstet Gynecol Surv 1993;48:357–387.
6. LaackTA, ThompsonKM, KoflerJM, et al. Comparison of trauma mortality and estimated cancer mortality from computed tomography during initial evaluation of intermediate-risk trauma patients. J Trauma 2011;70:1362–1365.
7. BrennerDJ, HallEJ. Computed tomography: an increasing source of radiation exposure. New Engl J Med 2007;357:2277–2284.
8. American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 51: chronic pelvic pain. Obstet Gynecol 2004;103:589–605.
9. LamvuG, WilliamsR, ZolnounD, et al. Long-term outcomes after surgical and nonsurgical management of chronic pelvic pain: one year after evaluation in a pelvic pain specialty clinic. Am J Obstet Gynecol 2006;195:591–598; discussion 598–600.
10. TrentM, BassD, NessRB, HaggertyC. Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study. Sex Transm Dis 2011;38:879–881.
11. NessRB, SoperDE, HolleyRL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–937.
12. GiamberardinoMA, De LaurentisS, AffaitatiG, et al. Modulation of pain and hyperalgesia from the urinary tract by algogenic conditions of the reproductive organs in women. Neurosci Lett 2001;304:61–64.
13. BerkleyKJ, CasonA, JacobsH, BradshawH, WoodE. Vaginal hyperalgesia in a rat model of endometriosis. Neurosci Lett 2001;306:185–188.
14. ChungMK, ChungRR, GordonD, JenningsC. The evil twins of chronic pelvic pain syndrome: endometriosis and interstitial cystitis. JSLS 2002;6:311–314.
15. DrozJ, HowardFM. Use of the Short-Form McGill Pain Questionnaire as a diagnostic tool in women with chronic pelvic pain. J Minim Invasive Gynecol 2011;18:211–217.
16. MensJM, VleemingA, StoeckartR, StamHJ, SnijdersCJ. Understanding peripartum pelvic pain. Implications of a patient survey. Spine 1996;21:1363–1369; discussion 1369–1370.
17. BarbieriRL. Stenosis of the external cervical os: an association with endometriosis in women with chronic pelvic pain. Fertil Steril 1998;70:571–573.
18. CarlsonKJ, MillerBA, FowlerFJ, Jr. The Maine Women's Health Study: I. Outcomes of hysterectomy. Obstet Gynecol 1994;83:556–565.
19. KjerulffKH, RhodesJC, LangenbergPW, HarveyLA. Patient satisfaction with results of hysterectomy. Am J Obstet Gynecol 2000;183:1440–1447.
20. AlmeidaEC, NogueiraAA, Candido dos ReisFJ, Rosa e SilvaJC. Cesarean section as a cause of chronic pelvic pain. Int J Gynecol Obstet 2002;79:101–104.
21. International Association for the Study of Pain. Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain 1979;6:249.
22. ZondervanKT, YudkinPL, VesseyMP, et al. Chronic pelvic pain in the community: symptoms, investigations, and diagnoses. Am J Obstet Gynecol 2001;184:1149–1155.
23. HowardFM, El-MinawiAM, SanchezRA. Conscious pain mapping by laparoscopy in women with chronic pelvic pain. Obstet Gynecol 2000;96:934–939.
24. DemcoLA. Effect on negative laparoscopy rate in chronic pelvic pain patients using patient assisted laparoscopy. JSLS 1997;1:319–321.
25. LongstrethGF, ThompsonWG, CheyWD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480–1491.
26. FordAC, CheyWD, TalleyNJ, et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med 2009;169:651–658.
27. HommaY, UedaT, TomoeH, et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int J Urol 2009;16:597–615.
28. HannoPM, BurksDA, ClemensJQ, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 2011;185:2162–2170.
29. BulunSE. Endometriosis. New Engl J Med 2009;360:268–279.
30. GuoSW. Epigenetics of endometriosis. Mol Hum Reprod 2009;15:587–607.
31. MeresmanGF, VighiS, BuquetRA, et al. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril 2000;74:760–766.
32. AbbottJA, HaweJ, ClaytonRD, GarryR. The effects and effectiveness of laparoscopic excision of endometriosis: a prospective study with 2–5 year follow-up. Hum Reprod 2003;18:1922–1927.
33. WalterAJ, HentzJG, MagtibayPM, CornellaJL, MagrinaJF. Endometriosis: correlation between histologic and visual findings at laparoscopy. Am J Obstet Gynecol 2001;184:1407–1411; discussion 1411–1403.
34. BeardRW, ReginaldPW, WadsworthJ. Clinical features of women with chronic lower abdominal pain and pelvic congestion. Br J Obstet Gynaecol 1988;95:153–161.
35. SteegeJF, StoutAL. Resolution of chronic pelvic pain after laparoscopic lysis of adhesions. Am J Obstet Gynecol 1991;165:278–281; discussion 281–283.
36. SuttonCJ, EwenSP, WhitelawN, HainesP. Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. Fertil Steril 1994;62:696–700.
37. AbbottJ, HaweJ, HunterD, et al. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril 2004;82:878–884.
38. ShakibaK, BenaJF, McGillKM, MingerJ, FalconeT. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet Gynecol 2008;111:1285–1292.
39. ZulloF, PalombaS, ZupiE, et al. Effectiveness of presacral neurectomy in women with severe dysmenorrhea caused by endometriosis who were treated with laparoscopic conservative surgery: a 1-year prospective randomized double-blind controlled trial. Am J Obstet Gynecol 2003;189:5–10.
40. CandianiGB, FedeleL, VercelliniP, BianchiS, Di NolaG. Presacral neurectomy for the treatment of pelvic pain associated with endometriosis: a controlled study. Am J Obstet Gynecol 1992;167:100–103.
41. VercelliniP, AimiG, BusaccaM, et al. Laparoscopic uterosacral ligament resection for dysmenorrhea associated with endometriosis: results of a randomized, controlled trial. Fertil Steril 2003;80:310–319.
42. SuttonC, PooleyAS, JonesKD, DoverRW, HainesP. A prospective, randomized, double-blind controlled trial of laparoscopic uterine nerve ablation in the treatment of pelvic pain associated with endometriosis. Gynaecol Endoscopy 2001;10:6.
43. FedeleL, BianchiS, ZanconatoG, et al. Tailoring radicality in demolitive surgery for deeply infiltrating endometriosis. Am J Obstet Gynecol 2005;193:114–117.
44. LingFW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol 1999;93:51–58.
45. AdamsonGD, KweiL, EdgrenRA. Pain of endometriosis: effects of nafarelin and danazol therapy. Int J Fert Menopaus Stud 1994;39:215–217.
46. HornsteinMD, YuzpeAA, BurryKA, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril 1995;63:955–962.
47. HornsteinMD, SurreyES, WeisbergGW, CasinoLA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998;91:16–24.
48. Perez-MarreroR, EmersonLE, FeltisJT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol 1988;140:36–39.
49. ParsonsCL, BensonG, ChildsSJ, et al. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol 1993;150:845–848.
50. van OphovenA, PokupicS, HeineckeA, HertleL. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol 2004;172:533–536.
51. PetersKM, CareyJM, KonstandtDB. Sacral neuromodulation for the treatment of refractory interstitial cystitis: outcomes based on technique. Int Urogynecol J Pelvic Floor Dysfunct 2003;14:223–228; discussion 228.
52. ComiterCV. Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study. J Urol 2003;169:1369–1373.
53. American College of Gastroenterology Task Force on Irritable Bowel, BrandtLJ, CheyWD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(Suppl 1):S1–S35.
54. DrossmanDA, CheyWD, JohansonJF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome: results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329–341.
55. FordAC, TalleyNJ, SchoenfeldPS, QuigleyEM, MoayyediP. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367–378.
56. EfskindPS, BernklevT, VatnMH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996;31:463–468.
57. ZijdenbosIL, de WitNJ, van der HeijdenGJ, RubinG, QuarteroAO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev 2009;(1):CD006442.
58. PetersAA, Trimbos-KemperGC, AdmiraalC, TrimbosJB, HermansJ. A randomized clinical trial on the benefit of adhesiolysis in patients with intraperitoneal adhesions and chronic pelvic pain. Br J Obstet Gynaecol 1992;99:59–62.
59. SwankDJ, Swank-BordewijkSC, HopWC, et al. Laparoscopic adhesiolysis in patients with chronic abdominal pain: a blinded randomised controlled multi-centre trial. Lancet 2003;361:1247–1251.
60. BrownCB, LucianoAA, MartinD, et al. Adept (icodextrin 4% solution) reduces adhesions after laparoscopic surgery for adhesiolysis: a double-blind, randomized, controlled study. Fertil Steril 2007;88:1413–1426.
61. WalkerEA, Roy-ByrnePP, KatonWJ, JemelkaR. An open trial of nortriptyline in women with chronic pelvic pain. Int J Psychiatry Med 1991;21:245–252.
62. GuthrieE, CreedF, DawsonD, TomensonB. A randomised controlled trial of psychotherapy in patients with refractory irritable bowel syndrome. Br J Psychiatry 1993;163:315–321.
63. SvedlundJ. Psychotherapy in irritable bowel syndrome. A controlled outcome study. Acta Psychiatr Scand Suppl. 1983;306:1–86.
64. FarquharCM, RogersV, FranksS, et al. A randomized controlled trial of medroxyprogesterone acetate and psychotherapy for the treatment of pelvic congestion. Br J Obstet Gynaecol 1989;96:1153–1162.
65. PetersAA, van DorstE, JellisB, et al. A randomized clinical trial to compare two different approaches in women with chronic pelvic pain. Obstet Gynecol 1991;77:740–744.
66. HaugstadGK, HaugstadTS, KirsteUM, et al. Continuing improvement of chronic pelvic pain in women after short-term Mensendieck somatocognitive therapy: results of a 1-year follow-up study. Am J Obstet Gynecol 2008;199:615 e611–618.
67. FoxSD, FlynnE, AllenRH. Mindfulness meditation for women with chronic pelvic pain: a pilot study. J Reprod Med 2011;56:158–162.
68. WilliamsRE, HartmannKE, SteegeJF. Documenting the current definitions of chronic pelvic pain: implications for research. Obstet Gynecol 2004;103:686–691.

References

1. SrivastaveR, ThakarR, SultanA. Female sexual dysfunction in obstetrics and gynecology. Obstet Gynecol Surv 2008;63:527–537.
2. ShifrenJL, BrigittaUM, RussoPA, SegretiA, JohannesCB. Sexual problems and distress in United States women. Obstet Gynecol 2008;112:970–978.
3. LaumannE, PaikA, RosenR. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537–544.
4. NusbaumMR, GambleG, SkinnerB, HeimanJ. The high prevalence of sexual concerns among women seeking routine gynecological care. Fam Pract 2000;49:229–232.
5. MyersLS, MorokofPJ. Physiological and subjective sexual arousal in pre- and postmenopausal women taking replacement therapy. Psychophysiology 1986;23:283–292.
6. NygaardI. Sexual dysfunction prevalence rates marketing or real?Obstet Gynecol 2008;11:968–969.
7. ShifrenJL, JohannesCB, MonzBU, et al. Help-seeking behavior of women with self-reported distressing sexual problems. J Women's Health 2009;18:461–468.
8. MercerCH, FentonKA, JohnsonAM, et al. Sexual function problems and help seeking behavior in Britain: national probability sample survey. BMJ 2003;327:426–427.
9. RosenRC, ShifrenJL, MonzBU, et al. Correlates of sexually related personal distress in women with low sexual desireJ Sex Med 2009;6:1549–1560.
10. ParkK, GoldsteinI, AndryC, et al. Vasculogenic female sexual dysfunction: the hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency. Int J Impot Res 1997;9:26–27.
11. MestonCM, FrohlichPF. The neurobiology of sexual function. Arch Gen Psychiatry 2000;57:1012–1030.
12. TarcanT, ParkK, GoldsteinI, et al. Histomorphometric analysis of age-related structural changes in human clitoral cavernosal tissue. J Urol 1999;161:940–943.
13. YangCC, BowenJR, KraftGH, et al. Cortical evoked potentials of the dorsal nerve of the clitoris and female sexual dysfunction in multiple sclerosis. J Urol 2000;164:2010–2013.
14. SipskiML, AlexanderCJ, RosenRC. Sexual response in women with spinal cord injuries: implications for our understanding of the able-bodied. J Sex Marital Ther 1999;25:11–22.
15. BergmarkK, Avall-LundqvistE, DickmanPW. Vaginal changes and sexuality in women with a history of cervical cancer. N Engl J Med 1999;340:1383–1389.
16. PhillipsNA. Female sexual dysfunction. Am Family Physician 2000;62:127–136.
17. GelenbergAJ, LaukesC, McGahueyC, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 2000;61:356–360.
18. SmithSM, O'KeaneV, MurayR. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002;181:49–55.
19. MastersWH, JohnsonVE. Human Sexual Response. Boston, MA: Little-Brown, 1966.
20. KaplanHS. The Sexual Desire Disorders. New York: Bruner/Mazel, 1995.
21. BassonR. Female sexual response: the role of drugs in the management of sexual dysfunction. Obstet Gynecol 2001;98:350–353.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. Washington, DC: American Psychiatric Association, 2000.
23. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: World Health Organization, 1994.
24. BassonR, BermanJ, BurnettA, et al. Report of the International Consensus Development Conference on Female Sexual Dysfunction: definitions and classifications. J Urol 2000;163:888.
25. LeiblumSR, ChiversML. Normal and persistent genital arousal in women: new perspectives. J Sex Marital Ther 2007;33:357–373.
26. AnnonJS. Behavioral Treatment of Sexual Problems. San Francisco, CA: Harper & Row, 1976.
27. ShifrenJL, BraunsteinGD, SimonJA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682–688.
28. SarrelP, DobayB, WiitaB. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. J Reprod Med 2000;43:847–856.
29. ArkW, CalliesF, Van VlijmenJC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999;341:1013–1020.
30. LabrieF, ArcherD, BouchardC, et al. Effect of intra-vaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16: 923–931.
31. FergusonDM, HosmaneB, HeimanJR. Randomized, placebo controlled, double blind, parallel design trial of the efficacy and safety of Zestra in women with mixed desire/interest/arousal/orgasm disorders. J Sex Marital Ther 2010;36:66–86.
32. JosefsonD. FDA approves device for female sexual dysfunction. BMJ 2000;320:1427.
33. BermanJR, AdhikariSP, GoldsteinI. Anatomy and physiology of female sexual function and dysfunction: classification, evaluation, and treatment options. Eur Urol 2000;38:20–29.
34. VemulapalliS, KurowskiS. Sildenafil relaxes rabbit clitoral corpus cavernosum. Life Sci 2000;67:23–29.
35. KaplanSA, ReisRB, KownIJ, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 1999;53:481–486.
36. CarusoS, IntelisanoG, LupoL, AgnelloC. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. Br J Obstet Gynecol 2001;108:623–628.
37. WisemanOJ, DasguptaR, FowlerCJ. A randomized double-blind, cross-over, placebo-controlled trial of sildenafil in neurogenic female sexual dysfunction. BJU Int 2003;91:89.
38. BermanJR, BermanL, GoldsteinI. Female sexual dysfunction: incidence, pathophysiology, evaluation, and treatment options, Urology 1999;54:385–391.
39. SommersF, CaspersH, EsdersK, et al. Measurement of vaginal and minor labial oxygen tension for the evaluation of female sexual function. J Urol 2001;165:1181–1184.
40. TaylorJE, RosenRC, LeiblumSR. Self-report assessment for female sexual function: psychometric evaluation of the Brief Index of Sexual Functioning for Women (BISF-W). Arch Sex Behav 1994;23:627–643.
41. RosenRC, BrownC, HeimanJ, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.
42. QuirkFH, HeimanJ, RosenR, et al. Development of a sexual function questionnaire for clinical trials of female sexual dysfunction. J Womens Health Gend Based Med 2002;11:277–289.
43. RosenRC. Assessment of female sexual dysfunction: review of validated methods. Fertil Steril 2002;77:S89–S93.
44. DerogatisLR. The Derogatis Interview for Sexual Functioning (DISF/DISF-R): an introductory report. J Sex Marital Ther 1997;23:291–296.
45. DerogatisLR, BurnettA, HeimanJ, et al. Development and continuing validation of the Female Sexual Distress Scale (FSDS). In 4th Annual Female Sexual Function Forum, Boston, October, 2001.
46. Center for Drug Evaluation and Research. Female Sexual Dysfunction: Clinical Development of Drug Products for Treatment. Rockville, MD: US Department of Health and Human Services, 2000.

References

1. PerovicS, MullerWEG. Pharmacological profile of hypericum extract: effect of serotonin uptake by postsynaptic receptors. Arztl Forsch 1995;45:1145–1148.
2. KalbR, Trautmann-SponselRD, KieserM. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients: a randomized double-blind multicenter trial. Pharmacopsychiatry 2001;34:96–103.
3. BrennerR, AxbelV, MadhusoodananS, et al. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther 2000;22:411–419.
4. BehnkeK, JensenGS, GraubaumHG, et al. Hypericum perjoratum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther 2002;19:43–52.
5. LindeK, RamirezG, MulrowCD, et al. St. John's wort for depression. BMJ 1996;313:253–258.
6. GasterB, HolroydJ. St. John's wort for depression: a systematic review. Arch Intern Med 2000;160:152–156.
7. SheltonRC, KellerMB, GelenberA, et al. Effectiveness of St. John's wort in major depression: a randomized controlled trial. JAMA 2001;285:1978–1986.
8. Hypericum Depression Trial Study Group. Effect of Hypericum perjoratum (St. John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002;287:1807–1814.
9. LindeK, BernerMM, KristonL. St. John's wort for major depression. Cochrane Database Syst Rev 2008;(4):CD000448.
10. StevinsonC, ErnstE. A pilot study of Hypericum perjoratum for the treatment of premenstrual syndrome. Br J Obstet Gynaecol 2000;107:870–876.
11. CanningS, WatermanM, OrsiN, et al. The efficacy of Hypericum perforatum (St. John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010;24:207–225.
12. ErnstE, RandJI, BarnesJ, et al. Adverse effects profile of herbal anti-depressant St. John's wort. Eur J Clin Pharmacol 1998;54:589–594.
13. Baede-van DijkPA, van GalenE, LekkerkerkerJF. Drug interactions of Hypericum perjoratum are potentially hazardous. Ned Tijdschr Geneesk 2000;144:811–812.
14. ErnstE. St. John's wort supplements endanger the success of organ transplantation. Arch Surg 2002;137:316–319.
15. Therapeutic Research Faculty. Natural Medicines Comprehensive Database. Stockton, CA: Therapeutic Research Faculty (http://www.naturaldatabase.com, accessed 20 November 2013).
16. JarryH, LeonhardtS, GorkowC, et al. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 1994;102:448–454.
17. LiuJ, BurdetteJE, SunY, et al. Isolation of linoleic acid as an estrogenic compound from the fruits of Vitex agnus castus L. (chaste-berry). Phytomedicine 2004;11:18–23.
18. LochEG, SelleH, BoblitzN. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containingVitex agnus castus. J Womens Health Gend Based Med 2000;9:315–320.
19. BergerD, SchaffnerW, SchraderE, et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet 2000;264:150–153.
20. SchellenbergR. Treatment for the premenstrual syndrome with Agnus castus fruit extract: prospective, randomized, placebo controlled study. BMJ 2001;322:134–137.
21. WetzigNR. Mastalgia: a 3 year Australian study. Aust N Z J Surg 1994;64:329–331.
22. CheungKL. Management of cyclical mastalgia in oriental women: pioneer experiment of using gamolenic acid (Efamast) in Asia. Aust N Z J Surg 1999;69:492–494.
23. BrautigamMR, BlommaertFA, VerleyeG, et al. Treatment of age-related memory complaints with Gingko biloba extract: a randomized double blind placebo-controlled study. Phytomedicine 1998;5:425–434.
24. FessendenJM, WittenbornW, ClarkeL. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg 2001;67:33–35.
25. ArenzA, KelinM, FleheK, et al. Occurrence of neurotoxic 4′-O-methylpyridoxine in ginkgo biloba leaves, ginkgo medications and Japanese ginkgo food. Planta Med 1996;62:548–551.
26. GrangerAS. Ginkgo biloba precipitating epileptic seizures. Age Aging 2001;30:523–525.
27. CohenAJ, BartlikB. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 1998;24:139–143.
28. KangBJ, LeeSJ, KimMD, et al. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol 2002;17:279–284.
29. OndrizekRR, ChanPJ, PattonWC, et al. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. Fertil Steril 1999;71:517–522.
30. HirataJD, SwierzLM, ZellB, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind placebo-controlled trial. Fertil Steril 1997;68:981–986.
31. AmatoP, ChristopheS, MellonPL. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause 2002;9:145–150.
32. MackeyR, EdenJ. Phytoestrogens and the menopause. Climacteric 1998;1:302–308.
33. BieberEJ, GellJS. Complementary and alternative medicine in the perimenopause and menopause. In YuanCS, BieberEJ (eds.) Textbook of Complementary and Alternative Medicine. New York: Parthenon, 2003, pp. 319–332.
34. BrzezinskiA, AdlercruetzH, ShaoulR, et al. Short-term effects of phytoestrogen-rich diet on postmenopausal women. Menopause 1997;2:89–94.
35. AlbertazziP, PansiniF, BonaccorsiG, et.al: The effect of dietary soy supplementation on hot flush. Obstet Gynecol 1998;91:6–11.
36. AlbertazziP, PansiniF, BottazziM, et al. Dietary soy supplementation and phytoestrogen levels. Obstet Gynecol 1999;94:229–231.
37. KronenberG, Fugh-BermanA. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805–813.
38. LethabyAE, BrownJ, MarjoribanksJ, et al. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Sys Rev 2007;(4):CD001395.
39. Tice, JA, EttingerB, EnsrudK, et al. Phytoestrogen supplements for the treatment of hot flashes: the isoflavone clover extract (ICE) study: a randomized controlled trial. JAMA 2003;290:207–214.
40. GellerSE, ShulmanLP, van BreemenRB, et al. Safety and efficacy of black cohost and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009;16:1156–1166.
41. WilcoxG, WahlquistML, BurgerHG, MedleyG. Oestrogenic effects of plant foods in postmenopausal women. BMJ 1990;301:905–906.
42. QuellaSK, LoprinziCL, BartonDL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group trial. J Clin Oncol 2000;18:1068–1074.
43. KomesaroffPA, BlackCV, CableV, et al. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric 2001;4:144–150.
44. LupuR, MehmiI, AtlasE, et al. Black cohosh, a menopausal remedy, does not have estrogenic activity and does not promote breast cancer cell growth. Int J Oncol 2003;23:1407–1412.
45. Seidlova-WuttkeD, HesseO, JarryH, et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17β. Eur J Endocrinol 2003;149:351–362.
46. StollW. Phytopharmaceutical influences on atrophic vaginal epithelium: double-blind study on Cimicifuga v an estrogen preparation. Therapeutickon 1987;1:23–32.
47. JacobsonJS, TroxelAB, KlausEJ, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739–2745.
48. UebelhackR, BiohmerJU, BraubaumHJ, et al. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006;107:247–255.
49. GuzmanG, KallwitzER, WojewodaC, et al. Liver injury with features mimicking autoimmune hepatitis following the use of black cohosh. Case Report Med 2009;2009:918156.
50. MahadyGB, Low DogT, BarrettML, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008;15:628–638.
51. Ang-LeeMK, MossJ, YuanCS. Herbal medicines and perioperative care. JAMA 2001;286:208–216.

References

1. SaltzmanLE, FanslowJ, McMahonP, ShelleyG. Intimate Partner Violence Surveillance: Uniform Definitions and Recommended Data Elements, version 1.0. Atlanta, GA: National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 1999.
2. SouthworthC, FinnJ, DawsonS, FraserC, TuckerS. Intimate partner violence, technology, and stalking. Violence Against Women 2007;13:842–856.
3. McFarlaneJ, HughesRB, NosekMA, et al. Abuse assessment screen-disability (AAS-D): measuring frequency, type, and perpetrator of abuse toward women with physical disabilities. J Womens Health Gend Based Med 2001;10:861–866.
4. CatalanoS. Intimate Partner Violence in the United States. Washington, DC: Bureau of Justice Statistics, 2007 (http://bjs.ojp.usdoj.gov/index.cfm?ty=pbdetail&iid=1000, accessed 12 February 2014).
5. MoraccoKE, RunyanCW, BowlingJM, EarpJAL. Women's experiences with violence: A national study. Women's Health Issues 2007;17:3–12.
6. HotalingGTS, DavidB. A risk marker analysis of assaulted wives. J Fam Violence 1990;5:1–13.
7. GazmararianJA, PetersenR, SpitzAM, et al. Violence and reproductive health: current knowledge and future research directions. Matern Child Health J 2000;4:79–84.
8. ChuSY, GoodwinMM, D'AngeloDV. Physical violence against US women around the time of pregnancy, 2004–2007. Am J Prevent Med 2010;38:317–322.
9. SibaiBM, EwellM, LevineRJ, et al. Risk factors associated with preeclampsia in healthy nulliparous women. Am J Obstet Gynecol 1997;177:1003–1010.
10. CoustanD. Gestational diabetes. In National Institutes of Diabetes and Digestive and Kidney Diseases. Diabetes in America, 2nd edn [NIH Publication 95-1468]. Bethesda, MD: National Institutes of Diabetes and Digestive and Kidney Diseases, 1995.
11. HeltonAS, McFarlaneJ, AndersonET. Battered and pregnant: a prevalence study. Am J Public Health 1987;77:1337–1339.
12. BallardTJ, SaltzmanLE, GazmararianJA, et al. Violence during pregnancy: measurement issues. Am J Public Health 1998;88:274–276.
13. KellermannAL, MercyJA. Men, women, and murder: gender-specific differences in rates of fatal violence and victimization. J Trauma 1992;33:1–5.
14. MoraccoKE, RunyanCW, ButtsJ. Femicide in North Carolina, 1991–1993, A statewide study of patterns and precursors. Homicide Stud 1998;4:422–446.
15. WadmanMC, MuellemanRL. Domestic violence homicides: ED use before victimization. Am J Emerg Med 1999;17:689–691.
16. BonomiAE, AndersonML, RivaraFP, ThompsonRS. Health care utilization and costs associated with physical and nonphysical-only intimate partner violence. Health Serv Res 2009;44:1052–1067.
17. RivaraFP, AndersonML, FishmanP, et al. Healthcare utilization and costs for women with a history of intimate partner violence. Am J Prevent Med 2007;32:89–96.
18. DrossmanDA, TalleyNJ, LessermanJ, OldenKW, BarreiroMA. Sexual and physical abuse and gastrointestinal illness: review and recommendations. Ann Intern Med 1995;123:782–794.
19. ScholleSH, RostK, GoldingJ. Physical abuse among depressed women. J Gen Intern Med 1998;13:607–613.
20. WallingMK, O'HaraMW, ReiterRC, et al. Abuse history and chronic pain in women: II. a multivariate analysis of abuse and psychological morbidity. Obstet Gynecol 1994;84:200–206.
21. McCauleyJ, KernDE, KolodnerK, DerogatisLR, BassEB. Relation of low-severity violence to women's health. J Gen Intern Med 1998;13:687–691.
22. CokerAL, SmithPH, McKeownRE, KingMJ. Frequency and correlates of intimate partner violence by type: physical, sexual, and psychological battering. Am J Public Health 2000;90:553–559.
23. McFarlaneJ, MalechaA, GistJ, et al. Intimate partner sexual assault against women and associated victim substance use, suicidality, and risk factors for femicide. Issues Mental Health Nursing 2005;26:953–967.
24. AlvarezJ, PavaoJ, MackKP, et al. Lifetime interpersonal violence and self-reported chlamydia trachomatis diagnosis among California women. J Women Health 2009;18:57–63.
25. SareenJ, PaguraJ, GrantB. Is intimate partner violence associated with HIV infection among women in the United States?Gen Hosp Psychiatry 2009 2009;31:274–278.
26. GeeRE, MitraN, WanF, ChavkinDE, LongJA. Power over parity: intimate partner violence and issues of fertility control. Am J Obstet Gynecol 2009;201:148 e1–7.
27. MillerE, DeckerMR, McCauleyHL, et al. Pregnancy coercion, intimate partner violence and unintended pregnancy. Contraception 2010;81:316–322.
28. DietzPM, GazmararianJA, GoodwinMM, et al. Delayed entry into prenatal care: effect of physical violence. Obstet Gynecol 1997;90:221–224.
29. BeydounHA, Al-SahabB, BeydounMA, TamimH. Intimate partner violence as a risk factor for postpartum depression among Canadian women in the Maternity Experience Survey. Ann Epidemiol 2010;20:575–583.
30. PetersenR, GazmararianJA, SpitzAM, et al. Violence and adverse pregnancy outcomes: a review of the literature and directions for future research. Am J Prevent Med 1997;13:366–373.
31. HoronIL, ChengD. Enhanced surveillance for pregnancy-associated mortality: Maryland, 1993–1998. JAMA 2001;285:1455–1459.
32. ChengD, HoronIL. Intimate-partner homicide among pregnant and postpartum women. Obstet Gynecol 2010;115:1181–1186.
33. McFarlaneJ, CampbellJC, SharpsP, WatsonK. Abuse during pregnancy and femicide: urgent implications for women's health. Obstet Gynecol 2002;100:27–36.
34. RodriguezMA, QuirogaSS, BauerHM. Breaking the silence: Battered women's perspectives on medical care. Arch Family Med 1996;5:153–158.
35. RodriguezMA, SheldonWR, BauerHM, Perez-StableEJ. The factors associated with disclosure of intimate partner abuse to clinicians. J Family Pract 2001;50:338–344.
36. McFarlaneJ, ParkerB, SoekenK, BullockL. Assessing for abuse during pregnancy: severity and frequency of injuries and associated entry into prenatal care. JAMA 1992;267:3176–3178.
37. American Congress of Obstetricians and Gynecologists. Screening Tools: Domestic Violence 2005–2010. Washington, DC: American Congress of Obstetricians and Gynecologists, 2011.
38. ChangJC, DeckerM, MoraccoKE, et al. What happens when health care providers ask about intimate partner violence? A description of consequences from the perspectives of female survivors. J Am Med Womens Assoc 2003;58:76–81.
39. ChangJC, DeckerMR, MoraccoKE, et al. Asking about intimate partner violence: advice from female survivors to health care providers. Patient Educ Couns 2005;59:141–147.
40. HathawayJE, WillisG, ZimmerB. Listening to survivors' voices: addressing partner abuse in the health care setting. Violence Against Women 2002;8:687–719.
41. GerbertB, CaspersN, BronstoneA, MoeJ, AbercrombieP. A qualitative analysis of how physicians with expertise in domestic violence approach the identification of victims. Ann Intern Med 1999;131:578–584.
42. GerbertB, CaspersN, MillikenN, et al. Interventions that help victims of domestic violence. A qualitative analysis of physicians' experiences. J Fam Pract 2000;49:889–895.
43. CampbellJC, WebsterD, Koziol-McLainJ, et al. Risk factors for femicide in abusive relationships: results from a multisite case control study. Am J Public Health 2003;93:1089–1097.
44. BuelSM, HarvardJD. Family violence: practical recommendations for physicians and the medical community. Womens Health Issues 1995;5:158–172.
45. CaralisPV, MusialowskiR. Women's experiences with domestic violence and their attitudes and expectations regarding medical care of abuse victims. S Med J 1997;90:1075–1080.
46. GerbertB, JohnstonK, CaspersN, et al. Experiences of battered women in health care settings: a qualitative study. Women Health 1996;24:1–17.
47. HambergerLK, AmbuelB, MarbellaA, DonzeJ. Physician interaction with battered women: the women's perspective. Arch Family Med 1998;7:575–582.
48. ChangJC, ClussPA, RanieriL, et al. Health care interventions for intimate partner violence: what women want. Womens Health Issues 2005;15:21–30.
49. GerbertB, AbercrombieP, CaspersN, LoveC, BronstoneA. How health care providers help battered women: the survivor's perspective. Women Health 1999;29:115–135.
50. McCawB, BauerHM, BermanWH, et al. Women referred for on-site domestic violence services in a managed care organization. Women Health 2002;35(2–3):23–40.
51. LandenburgerK. A process of entrapment in and recovery from an abusive relationship. Issues Ment Health Nurs 1989;10(3–4):209–227.
52. ClussPA, ChangJC, HawkerL, et al. The process of change for victims of intimate partner violence: support for a psychosocial readiness model. Womens Health Issues 2006;16:262–274.
53. McCloskeyLA, LichterE, WilliamsC, et al. Assessing intimate partner violence in health care settings leads to women's receipt of interventions and improved health. Public Health Rep 2006;121:435–444.

References

1. MitikeG, DeressaW. Prevalence and associated factors of female genital mutilation among Somali refugees in eastern Ethiopia: a cross-sectional study. BMC Public Health 2009, 9:264.
2. World Health Organization. Eliminating Female Genital Mutilation: An Interagency Statement. Geneva: World Health Organization. for UNAIDS, UNDP, UNECA, UNESCO, UNFPA, UNHCHR, UNHCR, UNICEF, UNIFEM, 2008.
3. AbdulcadirJ, MargairazC, BoulvainM, IrionO. Care of women with female genital mutilation/cutting. Swiss Med Wkly 2011;140:w13137.
4. RodriguezS. Rethinking the history of female circumcision and clitoroidectomy: American medicine and female sexuality in the late nineteenth century. J Hist Med Allied Sci 2008;63:323–347.
5. KandelaP. Sketches from the Lancet: Clitoridectomy. Lancet 1999;353:1453.
6. World Health Organization. Female genital mutilation: new knowledge spurs optimism. Prog Sex Reprod Health Res 2006;72:2–8.
7. World Health Organization. Female Genital Mutilation [Fact Sheet 241]. Geneva: World Health Organization, 2000 (http://www.who.int/mediacentre/factsheets/fs241/en/, accessed 18 Feburary 2014).
8. YoderP, AbderrahimN, ZhuzhuniA. Female Genital Cutting in the Demographic and Health Surveys: A Critical and Comparative Analysis [DHS Comparative Report 7]. Calverton, MD: ORC Macro, 2004.
9. UNICEF Innocenti Research Centre. Changing a Harmful Social Convention: Female Genital Mutilation/Cutting. Florence: UNICEF Innocenti Research Centre, 2005.
10. E1-ZanatyF, HusseinEM, ShawkyGA, WayAA, KishorS. Egypt Demographic and Health Survey, 1995. Calverton, MA: Macro International, 1995.
11. E1-ZanatyF, WayAA. Egypt Demographic and Health Survey 2000. Calverton, MA: Macro International, 2000.
12. Mali Ministry of Health. Demographic and Health Survey Mali, 2001. Calverton, MA: ORC Macro, 2001.
13. Mauritania Office of National Statistics. Demographic and Health Survey Mauritania, 2000–2001. Calverton, MA: ORC Macro, 2001.
14. Central Statistical Authority of Ethiopia. Demographic and Health Survey Ethiopia, 2000. Calverton, MA: ORC Macro, 2000.
15. UNICEF. Female Genital Mutilation/Female Genital Cutting: A Statistical Report. New York: UNICEF, 2005.
16. AnnasCL. Irreversible error: the power and prejudice of female genital mutilation. J Contemp Health Law Policy 1996;12:325–353.
17. MomohC, LadhaniS, LochrieDP, RymerJ. Female genital mutilation: analysis of the first twelve months of a southeast London specialist clinic. Br J Obstet Gynaecol 2001;108:186–191.
18. BillingU. Female genital mutilation: an injury, physical and mental harm. J Psychosom Obstet Gynaecol 2008;29:225–229.
19. TalleA. Transforming women into “pure” agnates: aspects of female infibulation in Somalia. In BrochDueV, RudieI, BleieT (eds.) Carved Flesh, Cast Selves: Gender Symbols and Social Practices. Oxford: Berg, 1993, pp. 83–106.
20. NourN, MichelsK, BryantA. Defibulation to treat female genital cutting: effect on symptoms and sexual function. Obstet Gynecol 2006;108:55–60.
21. MohamadS, ThabetSM, ThabetAS. Defective sexuality and female circumcision: the cause and the possible management. J Obstet Gynaecol Res 2003;29:12–19.
22. DirieM, LindmarkG. The risk of medical complications after femal circumcision. East Afr Med J 1992;69:479–482.
23. ArbesmanM, KahlerL, BuckG. Assessment of the impact of female circumcision on the gynecological genitourinary and obstetrical health problems of women from Somalia: literature review and case studies. Womens Health 1993;20:27–42.
24. WhitehornJ, AyonrindeO, MaingayS. Female genital mutilation: cultural and psychological implicationsSex Relationship Ther 2002;17(2).
25. EldefrawyM, LoftyG, DandashK, RefaatA, EyadaM. Female genital mutilation and its psychosexual impact. J Sex Marital Ther 2001;27:465–473.
26. El DareerA. Complications of female circumcision in the Sudan. Trop Doct 1983;13:131–133.
27. ShandallA. Circumcision and infibulation of female. Sudan Med J 1976;5:178–212.
28. MutenbeiIB, MwesigaMK. The impact of obsolete traditions on HIV/AIDS rapid transmission in Africa: the case of compulsory circumcision on young girls in Tanzania. Int Conf AIDS 1998;12:436.
29. OyugiC. Social cultural factors that promote female circumcision and how this predisposes women to HIV infection. Int Conf AIDS 1998;12:1011.
30. World Health Organization. A Systematic Review of the Health Complications of Female Genital Mutilation including Sequelae in Childbirth. Geneva: World Health Organization, 2000.
31. BanksE, MeirikO, FarleyT, et al. Female genital mutilation and obstetric outcome: WHO collaborative prospective study in six African countries. Lancet 2006;367:1835–1841.
32. LaxR. Socially sanctioned violence against women: female genital mutilation is its most brutal form. Clin Social Work J 2000;28:403–412.
33. Lightfoot-KleinH. Disability in female immigrants with ritually inflicted genital mutilation. Women Ther 1993;14:187–194.
34. BlackJ, DebelleG. Female genital mutilation in Britain. BMJ 1995;310:1590–1592.
35. ToubiaN. Female circumcision as a public health issue. N Engl J Med 1994;331:712–716.
36. Royal College of Obstetricians and Gynaecologists. Female Genital Mutilation [Statement 3]. London: Royal College of Obstetricians and Gynaecologists, 2003.
37. FoldesP, Louis-SylvestreC. Results of surgical clitoral repair after ritual excision: 453 cases. Gynecol Obstet Fertil 2006;34:1137–1141.
38. SerourGI. The issue of reinfibulation. Int J Gynecol Obstet 2010;109:93–96.
39. FIGO. Committee for the Study of Ethical Aspects of Human Reproduction and Women's Health, Ethical Issues in Obstetrics and Gynecology. London: FIGO,2009.
40. Royal College of Midwives. Female Genital Mutilation (Female Circumcision) [Position Paper 21]. London: Royal College of Midwives, 1998.
41. Joint WHO FIGOTask Force. Female circumcision (female genital mutilation). Int J Gynecol Obstet 1992;37:149.
42. FIGO. Recommendations on Ethical Issues in Obstetrics and Gynecology. London: FIGO, 2000.
43. World Health Organization. Female Genital Mutilation and Other Harmful Practices. Ending Female Genital Mutilation [WHO briefing Paper]. Geneva: World Health Organization, 2008 (http://www.who.int/reproductivehealth/topics/fgm/ending_fgm/en/index.html, accessed 17 February 2014).
44. RahmanA, ToubiaN (eds.). Female Genital Mutilation: A Guide to Laws and Policies Worldwide. London: Zed Books, 2000, p. 153.
45. British Medical Association. Female Genital Mutilation Caring for Patients and Child Protection. London: British Medical Association, 2011.

References

1. CoulterA, BradlowJ, AgassM, Martin-BatesC, TullochA. Outcomes of referrals to gynaecology outpatient clinics for menstrual problems: an audit of general practice records. Br J Obstet Gynaecol 1991;98:789–796.
2. FarquharCM, SteinerCA. Hysterectomy rates in the United States 1990–1997. Obstet Gynecol 2002;99:229–234.
3. CoteI, JacobsP, CummingD. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol 2002;100:683–687.
4. CollinsJ, CrosignaniPG. Endometrial bleeding. Hum Reprod Update 2007;13:421–431.
5. HellerDS. Pathologic basis for abnormal uterine bleeding with organic uterine pathologies. Menopause 2011;18:412–415.
6. LockwoodCJ. Mechanisms of normal and abnormal endometrial bleeding. Menopause 2011;18:408–411.
7. FraserIS, CritchleyHO, MunroMG, BroderM. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding?Hum Reprod 2007;22:635–643.
8. MunroMG, CritchleyHO, FraserIS. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril 2011;95:2204–2208.
9. WeissG, MaseelallP, SchottLL, et al. Adenomyosis a variant, not a disease? Evidence from hysterectomized menopausal women in the Study of Women's Health Across the Nation (SWAN). Fertil Steril 2009;91:201–206.
10. HallbergL, HogdahlAM, NilssonL, RyboG. Menstrual blood loss: a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45:320–351.
11. van EijkerenMA, ChristiaensGC, SixmaJJ, HaspelsAA. Menorrhagia: a review. Obstet Gynecol Surv 1989;44:421–429.
12. HurskainenR, GrenmanS, KomiI, et al. Diagnosis and treatment of menorrhagia. Acta Obstet Gynecol Scand 2007;86:749–757.
13. OehlerMK, ReesMC. Menorrhagia: an update. Acta Obstet Gynecol Scand 2003;82:405–422.
14. Clevenger-HoeftM, SyropCH, StovallDW, Van VoorhisBJ. Sonohysterography in premenopausal women with and without abnormal bleeding. Obstet Gynecol 1999;94:516–520.
15. McCauslandAM. Hysteroscopic myometrial biopsy: its use in diagnosing adenomyosis and its clinical application. Am J Obstet Gynecol 1992;166:1619–1626; discussion 1626–1628.
16. LasmarRB, DiasR, BarrozoPR, et al. Prevalence of hysteroscopic findings and histologic diagnoses in patients with abnormal uterine bleeding. Fertil Steril 2008;89:1803–1807.
17. FerenczyA. Pathophysiology of adenomyosis. Hum Reprod Update 1998;4:312–322.
18. KrassasGE, PontikidesN, KaltsasT, PapadopoulouP, BatrinosM. Menstrual disturbances in thyrotoxicosis. Clin Endocrinol (Oxf) 1994;40:641–644.
19. KrassasGE, PontikidesN, KaltsasT, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf) 1999;50:655–659.
20. WilanskyDL, GreismanB. Early hypothyroidism in patients with menorrhagia. Am J Obstet Gynecol 1989;160:673–677.
21. MoragianniVA, SomkutiSG. Profound hypothyroidism-induced acute menorrhagia resulting in life-threatening anemia. Obstet Gynecol 2007;110:515–517.
22. JamesAH, KouidesPA, Abdul-KadirR, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol 2009;201:12 e1–8.
23. American Congress of Obstetricians and Gynecologists. Committee Opinion No. 451: von Willebrand disease in women. Obstet Gynecol 2009;114:1439–1443.
24. LukesAS, KadirRA, PeyvandiF, KouidesPA. Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact. Fertil Steril 2005;84:1338–1344.
25. ClaessensEA, CowellCA. Acute adolescent menorrhagia. Am J Obstet Gynecol 1981;139:277–280.
26. OralE, CagdasA, GezerA, et al. Hematological abnormalities in adolescent menorrhagia. Arch Gynecol Obstet 2002;266:72–74.
27. van EijkerenMA, ChristiaensGC, HaspelsAA, SixmaJJ. Measured menstrual blood loss in women with a bleeding disorder or using oral anticoagulant therapy. Am J Obstet Gynecol 1990;162:1261–1263.
28. KimTH, LeeHH. Presenting features of women with uterine arteriovenous malformations. Fertil Steril 2010;94:2330 e7–10.
29. PetersonHB, JengG, FolgerSG, et al. The risk of menstrual abnormalities after tubal sterilization. US Collaborative Review of Sterilization Working Group. N Engl J Med 2000;343:1681–1687.
30. BayerSR, DeCherneyAH. Clinical manifestations and treatment of dysfunctional uterine bleeding. JAMA 1993;269:1823–1828.
31. Van VoorhisBJ, SantoroN, HarlowS, CrawfordSL, RandolphJ. The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause. Obstet Gynecol 2008;112:101–108.
32. CoulamCB, AnnegersJF, KranzJS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983;61:403–407.
33. FarquharCM, LethabyA, SowterM, VerryJ, BaranyaiJ. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol 1999;181:525–529.
34. IramS, MusondaP, EwiesAA. Premenopausal bleeding: when should the endometrium be investigated? A retrospective non-comparative study of 3006 women. Eur J Obstet Gynecol Reprod Biol 2010;148:86–89.
35. de KroonCD, de BockGH, DiebenSW, JansenFW. Saline contrast hysterosonography in abnormal uterine bleeding: a systematic review and meta-analysis. BJOG 2003;110:938–947.
36. DueholmM, LundorfE, HansenES, LedertougS, OlesenF. Evaluation of the uterine cavity with magnetic resonance imaging, transvaginal sonography, hysterosonographic examination, and diagnostic hysteroscopy. Fertil Steril 2001;76:350–357.
37. TogashiK, OzasaH, KonishiI, et al. Enlarged uterus: differentiation between adenomyosis and leiomyoma with MR imaging. Radiology 1989;171:531–534.
38. PhilippCS, FaizA, HeitJA, et al. Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia. Am J Obstet Gynecol 2011;204:209 e1–7.
39. KouidesPA. Menorrhagia from a haematologist's point of view. Part I: initial evaluation. Haemophilia 2002;8:330–338.
40. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.
41. AzzizR, HincapieLA, KnochenhauerES, et al. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 1999;72:915–925.
42. FarhiDC, NosanchukJ, SilverbergSG. Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 1986;68:741–745.
43. DijkhuizenFP, MolBW, BrolmannHA, HeintzAP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000;89:1765–1772.
44. Smith-BindmanR, KerlikowskeK, FeldsteinVA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998;280:1510–1517.
45. Di Spiezio SardoA, MazzonI, BramanteS, et al. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. Hum Reprod Update 2008;14:101–119.
46. CravelloL, StollaV, BretelleF, RogerV, BlancB. Hysteroscopic resection of endometrial polyps: a study of 195 cases. Eur J Obstet Gynecol Reprod Biol 2000;93:131–134.
47. VercelliniP, ZainaB, YaylayanL, et al. Hysteroscopic myomectomy: long-term effects on menstrual pattern and fertility. Obstet Gynecol 1999;94:341–347.
48. ZapataLB, WhitemanMK, TepperNK, et al. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010;82:41–55.
49. HighamJM, ShawRW. The effect of thyroxine replacement on menstrual blood loss in a hypothyroid patient. Br J Obstet Gynaecol 1992;99:695–696.
50. ScottJC, Jr., MusseyE. Menstrual patterns in myxedema. Am J Obstet Gynecol 1964;90:161–165.
51. PinkertonJV. Pharmacological therapy for abnormal uterine bleeding. Menopause 2011;18:453–461.
52. FraserIS, RomerT, ParkeS, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod 2011;26:2698–2708.
53. ShaabanMM, ZakherahMS, El-NasharSA, SayedGH. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception 2011;83:48–54.
54. LethabyA, IrvineG, CameronI. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008;(1):CD001016.
55. KaunitzAM, BissonnetteF, MonteiroI, et al. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010;116:625–632.
56. MilsomI, AnderssonK, AnderschB, RyboG. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991;164:879–883.
57. KaunitzAM, MeredithS, InkiP, KubbaA, Sanchez-RamosL. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009;113:1104–1116.
58. BlumenthalPD, DawsonL, HurskainenR. Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system. Int J Gynecol Obstet 2011;112:171–178.
59. HurskainenR, TeperiJ, RissanenP, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004;291:1456–1463.
60. OzdegirmenciO, KayikciogluF, AkgulMA, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril 2011;95:497–502.
61. LethabyA, AugoodC, DuckittK, FarquharC. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2007:CD000400.
62. ChimbiraTH, AndersonAB, NaishC, CopeE, TurnbullAC. Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo. Br J Obstet Gynaecol 1980;87:1152–1158.
63. BeaumontH, AugoodC, DuckittK, LethabyA. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev 2007;(4):CD001017.
64. LukesAS, MooreKA, MuseKN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010;116:865–875.
65. SundstromA, SeamanH, KielerH, AlfredssonL. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case–control study using the General Practice Research Database. BJOG 2009;116:91–97.
66. ThomasEJ, OkudaKJ, ThomasNM. The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991;98:1155–1159.
67. KadirRA, LukesAS, KouidesPA, FernandezH, GoudemandJ. Management of excessive menstrual bleeding in women with hemostatic disorders. Fertil Steril 2005;84:1352–1359.
68. ChiC, HuqFY, KadirRA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception 2011;83:242–247.
69. KilicS, YukselB, DoganayM, et al. The effect of levonorgestrel-releasing intrauterine device on menorrhagia in women taking anticoagulant medication after cardiac valve replacement. Contraception 2009;80:152–157.
70. KouidesPA, ByamsVR, PhilippCS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009;145:212–220.
71. El-NasharSA, HopkinsMR, FeitozaSS, et al. Global endometrial ablation for menorrhagia in women with bleeding disorders. Obstet Gynecol 2007;109:1381–1387.
72. SperoffL, GlassR, KaseN. Abnormal uterine bleeding. In Clinical Gynecologic Endocrinology and Infertility, 8th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2011, pp. 591–620.
73. DeVoreGR, OwensO, KaseN. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding: a double-blind randomized control study. Obstet Gynecol 1982;59:285–291.
74. JamesAH. Bleeding disorders in adolescents. Obstet Gynecol Clin North Am 2009;36:153–162.
75. HickeyM, HighamJ, FraserIS. Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev 2007 (4):CD001895.
76. American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010;115:206–218.
77. DavisA, GodwinA, LippmanJ, OlsonW, KafrissenM. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000;96:913–920.
78. MelmedS, CasanuevaFF, HoffmanAR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273–288.
79. AlHilliMM, HopkinsMR, FamuyideAO. Endometrial cancer after endometrial ablation: systematic review of medical literature. J Minim Invasive Gynecol 2011;18:393–400.

References

1. KernDE, RobertsJC. Preventive medicine in ambulatory practice. In BarkerLR, BurtonJR, ZievePD (eds.) Principles of Ambulatory Medicine, 4th edn. Baltimore, MD: Williams & Wilkins, 1995, pp. 17–29.
2. GrimesDA, SchulzKF. Uses and abuses of screening tests. Lancet 2002;359:881–884.
3. LingFW, PetersonH. Cancer screening. In LingFW, DuffP (eds.) Obstetrics and Gynecology: Principles for Practice. New York: McGraw-Hill, 2001, pp. 576–580.
4. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report, Atlanta, GA: Centers for Disease Control and Prevention, 1999, 2009, 2010.
5. SatcherD. Statement on Risk vs. Benefit of Vaccinations Before the House Committee on Government Reform August 3, 1999. Washington, DC: US Public Health Service, US Department of Health and Human Services, 1999.
6. Centers for Disease Control and Prevention. Vaccines and Immunizations 2014. Atlanta, GA: Centers for Disease Control and Prevention, 2014 (http://www.cdc.gov/vaccines/schedules/index.html, accessed 11 February 2014).
7. US Preventive Services Task Force. Screening for Hearing Loss in Older Adults. Rockville, MD: US Preventive Services Task Force, 2012 http://www.uspreventiveservicestaskforce.org/uspstf/uspshear.htm, accessed 11 February 2014).
8. RiesLAG, EisnerMP, KosaryCL, et al. (eds.) SEER Cancer Statistics Review, 1975–2008. Bethesda, MD: National Cancer Institute, 2008 (http://seer.cancer.gov/csr/1975_2008/, accessed 11 February 2014).
9. US Preventive Services Task Force. Screening for Skin Cancer. Rockville, MD: US Preventive Services Task Force, 2009.
10. HelfandM, MahonSM, EdenKB, et al. Screening for skin cancer. Am J Prev Med 2001;20(Suppl 3):47–58.
11. BerwickM, BeggCB, FineJA, et al. Screening for cutaneous melanoma by skin self-examination. JNCI 1996;88:17–23.
12. US Preventive Services Task Force. Counseling to Prevent Skin Cancer. Rockville, MD: US Preventive Services Task Force, 2003.
13. MarksR, FoleyPA, JolleyD, et al. The effect of regular sunscreen use on vitamin D levels in an Australian population. Results of a randomized controlled trial. Arch Dermatol. 1995;131:415–421.
14. CokkinidesVE, WeinstockMA, CardinezCJ, et al. Sun-safe practices in US youth and their parents, role of caregiver on youth sunscreen use. Am J Prev Med 2004;26:147–151.
15. Centers for Disease Control and Prevention. Physical activity trends: United States, 1990–1998. MMWR 2001;50:166–169.
16. ShawJ. The deadliest sin. Harvard Magazine Mar–Apr 2004; pp. 36–43.
17. US Preventive Services Task Force. Behavioral Counseling in Primary Care to Promote Physical Activity. Rockville, MD: US Preventive Services Task Force, 2002 (http://www.uspreventiveservicestaskforce.org/3rduspstf/physactivity/physactrr.htm, accessed 1 February 2014).
18. EdenKB, OrleansCT, MulrowCD, et al. Does counseling by clinicians improve physical activity? Summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;137:208–215.
19. SwinburnBA, WalterLG, ArrollB, et al. The green prescription study: a randomized controlled trial of written exercise advice provided by general practitioners. Am J Public Health 1998;88:288–291.
20. Writing Group for the Activity Counseling Trial Research Group. Effects of physical activity counseling in primary care – The activity counseling trial: a randomized controlled trial. JAMA 2001;286:677–687.
21. ProvinceMA, HadleyEC, HornbrookMC, et al. The effects of exercise on falls in elderly patients: a preplanned meta-analysis of the FICSIT trials. JAMA 1995;273:1341–1347.
22. US Department of Agriculture and US Department of Health and Human Services. Dietary Guidelines for Americans, 2010, 7th edn, Washington, DC: US Government Printing Office, 2010 (http://www.health.gov/dietaryguidelines/dga2010/DietaryGuidelines2010.pdf, accessed 1 February 2014).
23. PignoneMP, AmmermanA, FernandezL, et al. Counseling to promote a healthy diet in adults: a summary of the evidence for the US Preventive Services Task Force. Am J Prev Med 2003;24:84–101.
24. US Preventive Services Task Force. Behavioral Counseling in Primary Care to Promote a Healthy Diet. Rockville, MD: US Preventive Services Task Force, 2011 (http://www.uspreventiveservicestaskforce.org/uspstf/uspsdiet.htm, accessed 1 February 2014).
25. AhrensM. Home Structure Fires. Quincy, MA: National Fire Protection Association, 2011.
26. EnglandLJ, KendrickJS, WilsonHG, et al. Effects of smoking reduction during pregnancy on the birth weight of term infants. Am J Epidemiol 2001;154:694–701.
27. US Preventive Services Task Force. Counseling and Interventions to Prevent Tobacco Use and Tobacco-Caused Disease in Adults and Pregnant Women, Topic Page. Rockville, MD: US Preventive Services Task Force, 2009 (http://www.uspreventiveservicestaskforce.org/uspstf/uspstbac2.htm, accessed 1 February 2014).
28. FioreMC, JaenCR, BakerTB, et al. Treating Tobacco Use and Dependence: 2008 update [Clinical Practice Guideline]. Rockville, MD: US Department of Health and Human Services, Public Health Service, 2008 (http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf, accessed 1 February 2014).
29. American Congress of Obstetricians and Gynecologists. Committee Opinion No. 471: smoking cessation during pregnancy. Obstet Gynecol 2010;116:1241–1244.
30. FioreMC, HatsukamiDK, BakerTB. Effective tobacco dependence treatment. JAMA 2002;288:1768–1771.
31. US Preventive Services Task Force. Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse. Rockville, MD: US Preventive Services Task Force, 2004 (http://www.uspreventiveservicestaskforce.org/3rduspstf/alcohol/alcomisrs.htm, accessed 1 February 2014).
32. WhitlockEP, PolenMR, GreenCA, et al. Behavioral counseling interventions in primary care to reduce risk/harmful alcohol use by adults. Ann Intern Med 2004;140:558–569.
33. KnightJR, SherrittL, ShrierLA, HarrisSK, ChangG. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med 2002;156:607–614.
34. NewcombeDL, HumeniukRE, AliR. Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): report of results from the Australian site. Drug Alcohol Rev 2005;24:217–226.
35. BrownRL, RoundsLA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J 1995;94:135–140.
36. StaleyD, El-GuebalyN. Psychometric properties of the Drug Abuse Screening Test in a psychiatric patient population. Addict Behav 1990;15:257–264.
37. US Preventive Services Task Force. Screening for Illicit Drug Use. Rockville, MD: US Preventive Services Task Force, 2008 (http://www.uspreventiveservicestaskforce.org/uspstf/uspsdrug.htm, accessed 1 February 2014).
38. US Preventive Services Task Force. Counseling for Household and Recreational Injuries. Inactivated due to Lack of Evidence on the Benefit of Counseling. Rockville, MD: US Preventive Services Task Force, 2010 (http://www.uspreventiveservicestaskforce.org/uspstf/uspshrin.htm, accessed 1 February 2014).
39. Centers for Disease Control and Prevention, National Center for Injury Prevention. Falls: Older Adults 2013. Atlanta, GA: Centers for Disease Control and Prevention, 2013 (http://www.cdc.gov/HomeandRecreationalSafety/Falls/index.html, accessed 1 February 2014).
40. KrausJF, MorgensternH, FifeD, et al. Blood alcohol tests, prevalence of involvement, and outcomes following brain injury. Am J Public Health 1989;79:294–299.
41. MarineWM, KerwinEM, MooreEE, et al. Mandatory seatbelts: epidemiologic, financial, and medical rationale from the Colorado matched pairs study. J Trauma 1994;36:96–100.
42. KellyRB. Effect of a brief physician intervention on seat belt use. J Fam Pract 1987;24:630–632.
43. US Preventive Services Task Force. Counseling about Proper Use of Motor Vehicle Occupant Restraints and Avoidance of Alcohol Use to Prevent Injury. Rockville, MD: US Preventive Services Task Force, 2007 (http://www.uspreventiveservicestaskforce.org/uspstf/uspsmvin.htm, accessed 1 February 2014).
44. WilsonFA. StimpsonJP. Trends in fatalities from distracted driving in the United States, 1999 to 2008. Am J Public Health 2010;100:2213–2219.
45. US Preventive Services Task Force. Screening for Depression in AdultsRockville, MD: US Preventive Services Task Force, 2009 (http://www.uspreventiveservicestaskforce.org/uspstf/uspsaddepr.htm, accessed 1 February 2014).
46. US Preventive Services Task Force. Screening for Suicide Risk. Rockville, MD: US Preventive Services Task Force, 2004 (http://www.uspreventiveservicestaskforce.org/uspstf/uspssuic.htm, accessed 1 February 2014).
47. WhooleyMA, AvinsAL, MirandaJ, et al. Case-finding instruments for depression: two questions are as good as many. J Gen Intern Med 1997;12:439–445.
48. US Preventive Services Task Force. Screening for Iron Deficiency Anemia. Rockville, MD: US Preventive Services Task Force, 2006 (http://www.uspreventiveservicestaskforce.org/uspstf/uspsiron.htm, accessed 1 February 2014).
49. US Preventive Services Task Force. Screening for Lipid Disorders in Adults. Rockville, MD: US Preventive Services Task Force, 2008 (http://www.uspreventiveservicestaskforce.org/uspstf/uspschol.htm, accessed 1 February 2014).
50. PignoneMP, PhillipsCJ, AtkinsD, et al. Screening and treating adults for lipid disorders: a summary of the evidence. Am J Prev Med 2001;20(Suppl 3):77–89.
51. PignoneMP, PhillipsCJ, MulrowCD. Use of lipid lowering drugs for primary prevention of coronary heart disease: a meta-analysis of randomized trials. BMJ 2000;321:983–986.
52. HebertPR, GazianoJM, ChanKS, HennekensCH. Cholesterol lowering with statin drugs, risk of stroke and total mortality: an overview of randomized trials. JAMA 1997;278:313–321.
53. ShepherdJ, BlauwGJ, MurphyMB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–1630.
54. HelfandM. Screening for subclinical thyroid dysfunction in non-pregnant adults: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2004;140:128–141.
55. AttiaJ, MargettsP, GuyattG. Diagnosis of thyroid disease in hospitalized patients. Arch Intern Med 1999;159:658–665.
56. US Preventive Services Task Force. Screening for Thyroid Disease. Rockville, MD: US Preventive Services Task Force, 2004 (http://www.uspreventiveservicestaskforce.org/uspstf/uspsthyr.htm, accessed 1 February 2014).
57. CowieCC, RustKF, FordES, et al. Accounting of diabetes and pre-diabetes in the US population in 1988–1994 and 2005–2006. Diabetes Care 2009;32:287–294.
58. TuomilehtoJ, LindstromJ, ErikssonJG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350.
59. HarrisR, DonahueK, RathoreSS, et al. Screening adults for type 2 diabetes: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2003;138:215–229.
60. KahnR, AlperinP, EddyD, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1365–1374.
61. HarrisMI, FlegalKM, CowieCC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998;21:518–524.
62. US Preventive Services Task Force. Screening for Type 2 Diabetes Mellitus in Adults. Rockville, MD: US Preventive Services Task Force, 2008 (http://www.uspreventiveservicestaskforce.org/uspstf/uspsdiab.htm, accessed 1 February 2014).
63. SheridanS, PignoneM, DonahueK. Screening for high blood pressure: review of the evidence for the US Preventive Services Task Force. Am J Prev Med 2003;25:151–158.
64. US Preventive Services Task Force. Screening for High Blood Pressure in Adults. Rockville, MD: US Preventive Services Task Force, 2007 (http://www.uspreventiveservicestaskforce.org/uspstf/uspshype.htm, accessed 1 February 2014).
65. McTigueK, HarrisR, HemphillB, et al. Screening and interventions for obesity in adults: summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2003;139:933–949.
66. US Preventive Services Task Force. Screening for Obesity in Adults: Recommendations and Rationale. Rockville, MD: US Preventive Services Task Force, 2011 (http://www.uspreventiveservicestaskforce.org/uspstf/uspsobes.htm, accessed 1 February 2014).

References

1. HookEB. Rates of chromosome abnormalities at different maternal ages. Obstet Gynecol 1981;58:282.
2. HookEB, CrossPK, SchreinemachersDM. Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA 1983;249:2034–2038.
3. OlshanAF, SchnitzerPG, BairdPA. Paternal age and the risk of congenital heart defects. Teratology 1994;50:80–84.
4. BennettRL, MotulskyAG, BittlesA, et al. Genetic counseling and screening of consanguineous couples and their offspring: recommendations of the National Society of Genetic Counselors. J Genet Couns 2002;11:97–119.
5. EhrenbergHM, DierkerL, MilluzziC, MercerBM. Low maternal weight, failure to thrive in pregnancy, and adverse pregnancy outcomes. Am J Obstet Gynecol 2003;189:1726–1730.
6. LamPK, TorfsCP, BrandRJ. A low pregnancy body mass is a risk factor for an offspring with gastroschisis. Epidemiology 1999;10:17–21.
7. RosenbergTJ, GarbersS, ChavkinW, Chiasson, MA. Prepregnancy weight and adverse perinatal outcomes in an ethnically diverse population. Obstet Gynecol 2003;102:1022–1027.
8. DoddJM, GrivellRM, NguyenAM, et al. Maternal and perinatal outcomes by body mass index. Aust N Z J Obstet Gynaecol 2011;51:136–140.
9. WatkinsML, RasmussenSA, HoneinMA, et al. Maternal obesity and risk for birth defects. Pediatrics 2003;111:1152–1158.
10. HaradaM. Congenital minamata disease: intrauterine mercury poisoning. Teratology 1978;18:285–288.
11. MyersGJ, DavidsonPW, CoxC, et al. Prenatal methylmercury exposure from ocean fish consumption in the Seychelles child development study. Lancet 2003;361:1686–1692.
12. US Environment Protection Agency. What You Need to Know about Mercury in Fish and Shellfish. Washington, DC: US Environment Protection Agency, 2004 (http://www.epa.gov/waterscience/fishadvice/advice.html, accessed 1 February 2014; Tel. 1-800-723-3366).
13. Centers for Disease Control and Prevention. Recommendations for use of folic acid to reduce number of spina bifida cases and other neural tube defects. JAMA 1993;269:1233–1238.
14. OlshanAF, SmithJC, BondyML, et al. Maternal vitamin use and reduced risk of neuroblastoma. Epidemiology 2002;13:575–580.
15. Hernandez-DizaS, WerlerMM, AlexanderMW, MitchellAA. Folic acid antagonists during pregnancy and the risk of birth defects. N Eng J Med 2000;343:1608–1614.
16. GroenenPM, PeerPG, WeversRA, et al. Maternal myo-inositol, glucose, and zinc status is associated with the risk of offspring with spina bifida. Am J Obstet Gynecol 2003;189:1713–1719.
17. MastroiacovoP, MazzoneT, AddisA, et al. High vitamin A intake in early pregnancy and major malformations: a multicenter prospective controlled study. Teratology 1999;59:7–11.
18. GreenMF, HareJW, ClohertyJP, et al. First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology 1989;39:225–231.
19. GordanM, LandonM, SamuelsP, et al. Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy. Obstet Gynecol 1996;87:401–409.
20. ChewEY, MillsJL, MetzgerBE, et al. Metabolic control and progression of retinopathy. Diabetes Care 1995;18:631–637.
21. ReyE, CouturierA. The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol 1994;171:410–416.
22. BarrM II. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994;50:399–409.
23. TabacovaS, KimmelCA, WallK. Atenolol developmental toxicity: animal-to-animal comparisons. Birth Defects Res 2003;67:181–192.
24. RouseB, AzenC, KochR, et al. Maternal phenylketonuria collaborative study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae. Am J Med Gen 1997;69:89–95.
25. MitchellJJ, TrakadisYJ, ScriverCR. Phenylalanine hydroxylase deficiency. Genet Med 2011;13:697–707.
26. Delgado-Escueta AyJanz D. Consensus guidelines: preconception counseling management, and care of the pregnant woman with epilepsy. Neurology 1992;42(Suppl 5): 149–160.
27. TomsonT, BattinoD, BonizzoniE, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609–617.
28. Molgaard-NielsenD, HviidA. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011;305:1996–2002.
29. Van DrielD, WesselingJ, SauerPJJ, et al. Teratogen update: fetal effects after in utero exposure to coumarins. Overview of cases, follow-up findings, and pathogenesis. Teratology 2002;66:127–140.
30. ChristianMS, BrentRL. Teratogen update: evaluation of the reproductive and developmental risks of caffeine. Teratology 2001;64:51–78.
31. WengX, OdouliR, LiD. Maternal caffeine consumption during pregnancy and the risk of miscarriage: a prospective cohort study. Am J Obstet Gynecol 2008;198:279–281.
32. ShepardTH, BrentRL, FriedmanJM, et al. Update on new developments in the study of human teratogens. Teratology 2002;65:153–161.
33. D'AngeloD, WilliamsL, MorrowB, et al. Preconception and interconception health status of women who recently gave birth to a live-born infant: pregnancy risk assessment monitoring system (PRAMS), United States, 26 reporting areas 2004. MMWR 2007;56:1–35.
34. HortaBL, VictoraCG, MenezesAM, BarrosHR. Low birthweight, preterm births and intrauterine growth retardation in relation to maternal smoking. Paediatr Perinat Epidemiol 1997;11:140–151.
35. SokolRJ, MartierSS, AgerJW. The T-ACE questions: practical prenatal detection of risk-drinking. Am J Obstet Gynecol 1989;160:863–868.
36. NagyF, PendergrassPB, BowenDC, YeagerJC. A comparative study of cytological and physiological parameters of semen obtained from alcoholics and non-alchoholics. Alcohol Alcoholism 1986;21:17–23.
37. MartinSL, MackieL, KupperLL, et al. Physical abuse of women before, during, and after pregnancy. JAMA 2001;285:1581–1584.
38. MilunskyA, UlcickasM, RothmanK. Maternal heat exposure and neural tube defects. JAMA 1992;268:882–885.

References

1. Commission on Chronic Illness (ed.). Chronic Illness in the United States, Vol. 1. Cambridge, MA: Harvard University Press, 1957.
2. WilsonJMG, JungerG (eds.) Principles and Practice of Screening for Disease [Public Health Paper No. 34]. Geneva: World Health Organization, 1968.
3. HakamaM, ChamberlainJ, DayNE, et al. Evaluation of screening programmes for gynaecological cancer. Br J Cancer 1985;52:669–673.
4. MoscickiAB, ShiboskiS, BroeringJ, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277–284.
5. NobbenhuisMAE, WalboomersJMM, HelmerhorstTJM, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20–25.
6. EifelPJ, VerekJS, ThigpenJT. Cancer of the cervix, vagina, and vulva. In DeVitaVT Jr., HellmanS, RosenbergSA (eds.) Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001.
7. StolerMH, SchiffmanMfor the Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500–1505.
8. KivlahanC, IngramE. Papanicolaou smears without endocervical cells: are they inadequate?Acta Cytol 1986;30:258.
9. HildesheimA, SchiffmanMH, GravittPE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235–240.
10. OguchiM, KomuraJ, TagamiH, et al. Ultrastructural studies of spontaneously regressing plane warts: macrophages attack verruca-epidermal cells. Arch Dermatol Res 1981;270:403–411.
11. BoschFX, LorinczA, MunozN, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244–265.
12. BurdEM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1–17.
13. KossL, DurfeeG. Unusual patterns of squamous epithelium of the uterine cervix: cytologic and pathologic study of koilocytotic atypia. Ann NY Acad Sci 1956;63:1235–1240.
14. MeiselsA, FortinR, RoyM. Condylomatous lesions of the cervix. 2. Cytologic, colposcopic and histopathologic study. Acta Ctyol 1977;21:379–390.
15. BonnezW, ReichmanRC. Papillomaviruses: In MandellGL, BennettJE, DolinR (eds.) Principles and Practice of Infectious Disease, 5th edn. Philadelphia, PA: Churchill Livingstone, 2000.
16. KienzlerJL, LemoineMT, OrthG, et al. Humoral and cell-mediated immunity to human papillomavirus type 1 (HPV-1) in human warts. Br J Dermatol 1983;108:665–672.
17. BonnezW, DaRinC, RoseRC, et al. Use of human papillomavirus type 11 virions in an ELISA to detect specific antibodies in humans with condylomata acuminata. J Gen Virol 1991;72:1343–1347.
18. BonnezW, KashimaHK, LeventhalB, et al. Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis. Virology 1992;188:384–387.
19. HoGY, BiermanR, BeardsleyL, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–428.
20. RichardsonH, KelsallG, TellierP, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12:485–490.
21. BrownDR, RawlingsK, HandyV, et al. Human papillomavirus detection by hybrid capture in paired cervicovaginal lavage and cervical biopsy specimens. J Med Virol 1996;48:210–214.
22. LondesboroughP, HoL, TerryG, et al. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996;69:364–368.
23. KoutskyLA, HolmesKK, CritchlowCW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272–1278.
24. CuzickJ, SzarewskiA, CubieH, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871–1876.
25. American Society for Colposcopy and Cervical Pathology. Histology of the Normal Cervix. Frederick, MD: American Society for Colposcopy and Cervical Pathology (http://www.asccp.org/Members/Practice-Management-Full-Access/Cervix/Histology-of-the-Normal-Cervix, accessed 3 January 2014).
26. HutchinsonM, FertittaL, GoldbaumB, et al. Cervex-Brush and Cytobrush: comparison of their ability to sample abnormal cells for cervical smears. J Reprod Med 1991;36:581–586.
27. Martin-HirschP, LilfordR, JarvisG, et al. Efficacy of cervical-smear collection devices: a systematic review and meta-analysis. Lancet 1999;354:1763–1770.
28. GutmanS. FDA clarifies labeling of liquid-based systems. Acta Cytol 2000;44:1120.
29. ArbynM, BergeronC, KlinkhamerP, et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008;111:167–170.
30. BlackmanDK, BennettEM, MillerDS. Trends in self-reported use of mammograms (1989–1997) and Papanicolaou tests (1991–1997): Behavioral Risk Factor Surveillance System. MMWR CDC Surveill Summ 1999;48:1–22.
31. SwanJ, BreenN, CoatesRJ, et al. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 2003;97:1528–1540.
32. HensonRM, WyattSW, LeeNC. The National Breast and Cervical Cancer Early Detection Program: a comprehensive public health response to two major health issues for women. J Public Health Manag Pract 1996;2:36–47.
33. Centers for Disease Control and Prevention. National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Atlanta, GA: Centers for Disease Control and Prevention, 2012 (http://www.cdc.gov/cancer/nbccedp/data/summaries/national_aggregate.htm, accessed 21 November 2013).
34. US Preventive Services Task Force. Task Force recommendations. Ann Intern Med 2012;156:880–891.
35. SaslowD, SolomanD, LawsonH, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guideline for the Prevention and Early Detection of Cervical Cancer. CA Cancer J Clin 2012;62:147–172.
36. American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 109: clinical management guidelines for obstetrician-gynecologists – cervical cytology screening. Obstet Gynecol 2012;20:1222–1238.
37. SiebersAG, KlinkhamerPJ, GrefteJM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 2009;302:1757–1764.
38. WrightTC, MassadSL, DuntonCJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007:346–355.
39. MillerAB, AndersonG, BrissonJ, et al. Report of a national workshop on screening for cancer of the cervix. CMAJ 1991;145:1301–1325.
40. MillerAB, KnightJ, NarodS. The natural history of cancer of the cervix, and the implications for screening policy. In MillerAB, ChamberlainJ, DayNE, et al. (eds.) Cancer Screening. Cambridge, UK: Cambridge University Press, 1991, pp. 144–152.
41. MoscickiBA, CoxJT. Practice Improvement in Cervical Screening and Management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Dis 2010:14:73–80.
42. MillerAB. The (in)efficiency of cervical screening in Europe. Eur J Cancer 2002;38:321–326.
43. SasieniP, AdamsJ, CuzickJ. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003;89:88–93.
44. MillerAB. Cervical Cancer Screening Programmes: Managerial Guidelines. Geneva: World Health Organization, 1992.
45. IARC Working Group on Evaluation of Cervical Cancer Screening Programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. BMJ 1986;293:659–664.
46. ColeP, MorrisonAS. Basic issues in population screening for cancer. JNCI 1980;64:1263–1272.
47. YuSZ, MillerAB, ShermanGJ. Optimising the age, number of tests, and the test interval for cervical screening in Canada. J Epidemiol Community Health 1982;36:1–10.
48. van OortmarssenGJ, HabbemaJD. Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears. Int J Epidemiol 1995;24:3007.
49. MillerAB. Failures of cervical cancer screening. Am J Public Health 1995;85:761–762.
50. AshleyDJ. Evidence for the existence of two forms of cervical carcinoma. J Obstet Gynaecol Br Commonw 1966;73:382–389.
51. CelentanoDD, KlassenAC, WeismanCS, et al. Duration of relative protection of screening for cervical cancer. Prev Med 1989;18:411–422.
52. HerbertA, SteinK, BryantTN, et al. Relation between the incidence of invasive cervical cancer and the screening interval: is a five year interval too long?J Med Screen 1996;3:140–145.
53. GoldieSJ, KuhnL, DennyL, et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:3107–3115.
54. MillerMG, SungHY, SawayaGF, et al. Screening interval and risk of invasive squamous cell cervical cancer. Obstet Gynecol 2003;101:29–37.
55. SawayaGF, McConnellKJ, KulasingamSL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003;349:1501–1509.
56. CecchiniS, IossaA, CiattoS. Upper age limit for cervical cancer screening. Eur J Cancer 1996;32A:180.
57. ColemanD, DayN, DouglasG, et al. European guidelines for quality assurance in cervical cancer screening: Europe Against Cancer Programme. Eur J Cancer 1993;29A(Suppl 4):S1–S38.
58. SolomonD, DaveyD, KurmanR, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002;287:2114–2119.
59. WrightTC Jr., CoxJT, MassadLS. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. J Lower Genital Tract Dis 2002;6:127–143.
60. KoutskyLA, for the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. JNCI 2000;92:397–402.
61. MitchellMF, Tortolero-LunaG, WrightT, et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. JNCI Monogr 1996;21:17–25.
62. MelnikowJ, NuovoJ, WillanA, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92:727–735.
63. JonesRW. The natural history of lower genital tract precancer: historical perspective. In MacLeanA, SingerA, CritchleyH (eds.) Lower Genital Tract Neoplasia. London: Royal College of Obstetricians and Gynaecologists, 2004, pp. 69–81.
64. YostNP, SantosoJT, MclntireDD, IliyaFA. Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. Obstet Gynecol 1999;93:359–362.
65. American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 140: management of abnormal cervical cancer screening test results and cervical cancer precursors. Obstet Gynecol 2013;122:1338–1367.
66. MassadLS, RiesterKA, AnastosKM, et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group. J Acquir Immune Defic Syndr 1999;21:33–41.
67. HolcombK, MatthewsRP, ChapmanJE, et al. The efficacy of cervical conization in the treatment of cervical intraepithelial neoplasia in HIV-positive women. Gynecol Oncol 1999;74:428–431.
68. SelikRM, RabkinCS. Cancer death rates associated with human immunodeficiency virus infection in the United States. JNCI 1998;90:1300–1302.
69. FrischM, BiggarR, GoedertJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. JNCI 2000;92:1500–1510.
70. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010. MMWR 2010;59(RR-12):44–47.
71. JonesBA, NovisDA. Follow-up of abnormal gynecologic cytology: a college of American Pathologists Q-probes study of 16 132 cases from 306 laboratories. Arch Pathol Lab Med 2000;124:665–671.
72. RonnettBM, ManosMM, RansleyJE, et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol 1999;30:816–825.
73. DuskaLR, FlynnCF, ChenA, et al. Clinical evaluation of atypical glandular cells of undetermined significance on cervical cytology. Obstet Gynecol 1998;91:278–282.
74. ZweizigS, NollerK, RealeF, et al. Neoplasia associated with atypical glandular cells of undetermined significance on cervical cytology. Gynecol Oncol 1997;65:314–318.
75. GoffBA, AtanasoffP, BrownE, et al. Endocervical glandular atypia in Papanicolaou smears. Obstet Gynecol 1992;79:101–104.
76. TaylorR, GuerrieriJ, NashJ, et al. Atypical cervical cytology: colposcopic follow-up using the Bethesda system. J Reprod Med 1993;38:443–447.
77. LavertyC, FarnsworthA, ThurloeJ, et al. The reliability of a cytological prediction of cervical adenocarcinoma in situ. Aust N Z J Obstet Gynaecol 1988;28:307–312.
78. LeeK, MannaE, St JohnT. Atypical endocervical glandular cells: accuracy of cytologic diagnosis. Diagn Cytopathol 1995;71:894–897.
79. RiesLAG, EisnerMP, KosaryCL, et al. SEER Cancer Statistics Review, 1975–2002. Bethesda, MD: National Cancer Institute, 2004.
80. BousfieldL, PaceyF, YoungQ, et al. Expanded cytologic criteria for the diagnosis of adenocarcinoma in situ of the cervix and related lesions. Acta Cytol 1980;24:283–296.
81. AyerB, PaceyF, GreenbergM, BousfieldL. The cytologic diagnosis of adenocarcinoma in situ of the cervix uteri and related lesions. 1. Adenocarcinoma in situ. Acta Cytol 1987;31:397–411.
82. GloorE, HurlimannJ. Cervical intraepithelial glandular neoplasia (adenocarcinoma in situ and glandular dysplasia): a correlative study of 23 cases with histologic grading, histochemical analysis of mucins, and immunohistochemical determination of the affinity for four lectins. Cancer 1986;58:1272–1280.
83. DenehyTR, GregoriCA, BreenJL. Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix. Obstet Gynecol 1997;90:1–6.
84. UrsinG, PikeMC, Preston-MartinS, et al. Sexual, reproductive, and other risk factors for adenocarcinoma of the cervix: results from a population-based case–control study. Cancer Causes Control 1996;7:391–401.
85. TaseT, OkagakiT, ClarkBA, et al. Human papillomavirus DNA in adenocarcinoma in situ, microinvasive adenocarcinoma of the uterine cervix, and coexisting cervical squamous intraepithelial neoplasia. Int J Gynecol Pathol 1989;8:8–17.
86. DugganMA, BenoitJL, McGregorSE, et al. Adenocarcinoma in situ of the endocervix: human papillomavirus determination by dot blot hybridization and polymerase chain reaction amplification. Int J Gynecol Pathol 1994;13:143–149.
87. AndersonMC, HartleyRB. Cervical crypt involvement by intraepithelial neoplasia. Am J Obstet Gynecol 1980;55:546–550.
88. Martin-HirschPL, ParaskevaidisE, KitchenerH. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2000;(2):CD001318.
89. MitchellMF, Tortolero-LunaG, CookE, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998;92:737.
90. DemopoulosRI, HorowitzLF, VamvakasEC. Endocervical gland involvement by cervical intraepithelial neoplasia grade III: predictive value for residual and/or recurrent disease. Cancer 1991;68:1932.
91. PrendivilleW. Treatment of grade 3 cervical intraepithelial neoplasia. In PrendivilleW, RitterJ, TattS, TwiggsL (eds.) Colposcopy Management Options. London: Saunders, 2003, pp. 129–135.
92. FlannellyG, BolgerB, FawziH, et al. Follow up after LLETZ: could schedules be modified according to risk of recurrence?. Br J Obstet Gynaecol 2001;108:1025–1030.
93. FlannellyG, LanghanH, JandialL, et al. A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1997;104:718–722.
94. BurkeL. The use of the carbon dioxide laser in the therapy of cervical intraepithelial neoplasia. Am J Obstet Gynecol 1982;144:377–380.
95. TownsendDE. Cryosurgery for CIN. Obstet Gynecol Surv 1979;34:828.
96. LarssonG, GullbergB, GrundsellH. A comparison of complications of laser and cold knife conization. Obstet Gynecol 1983;62:213–217.
97. BaggishM, DorseyJ, AdelsonM. A ten-year experience treating cervical intraepithelial neoplasia with CO2 laser. Am J Obstet Gynecol 1989;161:60–68.
98. HatchK, HackerN. Intraepithelial disease of the cervix, vagina and vulva. In BerekJ, AdashiE, HillardP (eds.) Novak's Gynecology, 12th edn. Baltimore, MD: Williams & Wilkins, 1996, pp. 447–474.
99. KatkiHA, KinneyWK, FettermanB, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet 2011;12:663.
100. RoncoG, Giorgi-RossiP, CarozziF, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet 2010;11:249–257.
101. NauclerP, RydW, TornbergS, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589–1597.
102. BulkmansNWJ, BerkhofJ, RozendaalL, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomized controlled implementation trial. Lancet 2007;370:1764–1772.
103. MayrandMH, Duarte-FrancoE, RodriguesIfor the Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;356:1579.
104. GoldieSJ, KimJJ, WrightTC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103:619–631.
105. DominitzJA, ProvenzaleD. Patient preferences and quality of life associated with colorectal cancer screening. Am J Gastroenterol 1997;92:2171–2178.
106. LawrenceVA, GafniA, KroenkeK. Evidence-based vs. emotion-based medical decision-making: routine preoperative HIV testing vs. universal precautions. J Clin Epidemiol 1993;46:1233–1236.
107. WardJ. Population-based mammographic screening: does “informed choice” require any less than full disclosure to individuals of benefits, harms, limitations, and consequences?Aust N Z J Public Health 1999;23:301–304.
108. MarteauTM, SeniorV, SasieniP. Women's understanding of a “normal smear test result”: experimental questionnaire based study. BMJ 2001;322:526–528.
109. ArbynM, KyrgiouM, SimoensC, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284.

References

1. HinselmannH. Verbesserung der inspektionsmoglichkeiten von Vulva Vagina and Portio. [Improvement of inspection facility of vulva, vagina and porto.] Muchner Med Wochenschr 1925: 72:1733–1742.
2. KurmanRJ, HensonDE, HerbstAL, et al. Interim guidelines for management of abnormal cervical cytology. JAMA 1994;271:1886–1869.
3. CoxJT, SchiffmanM, SolomonD. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003;188:1406–1412.
4. GuidoR, SchiffmanM, SolomonD, BurkeL, Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance; a two-year prospective study. Am J Obstet Gynecol 2003;188:1401–1405.
5. MitchellMF, SchottenfeldD, Zortolero-LunaG, et al. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1988;91:626–631.
6. HopmanEH, KenemansP, HelmerhorstTJ, et al. Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature. Gynecol Oncol Surv 1998;53:97–106.
7. BenedetJL, van de NiewenhofHP, NeeshamDE, et al. An analysis of 84 244 patients from British Columbia cytology–colposcopy program. Gynecol Oncol 2004;92:127–134.
8. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383–1392.
9. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of low grade squamous intraepithelial lesion. Am J Obstet Gynecol 2003;188:1393–1400.
10. MassadLS, HalperinCJ, BittermanP. Correlation between colposcopically directed biopsy and cervical loop excision. Gynecol Oncol 1996;60:400–403.
11. MassadLS, JeronimoJ, KatkiHA, SchiffmanM. The accuracy of colposcopic grading for detection of high grade cervical intraepithelial neoplasia. J Low Genit Tract Dis 2009;13:137–144.
12. PretoriusRG, ZhangWH, BelinsonJL, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004;191:430–434.
13. BenedetJL, MatisicJP, BertrandMA. The quality of community colposcopic practice. Obstet Gynecol 2004;103:545–548.
14. SideriM, SplotiN, SpinaciL. et al. Interobserver variability of colposcopic interpretations and consistency with final histologic results. J Low Genit Tract Dis 2004;8:212–216.
15. BekkersRL, van de NieuwenhofHP, NeeshamDE, et al. Does experience in colposocopy improve identification of high grade abnormalities?Eur J Obstet Gynecol Reprod Biol 2008;141:75–78.
16. HopmanEH, VoorhostFJ, KenemansP, et al. Observer agreement on interpreting colposcopic images of CIN. Gynecol Oncol 1995;58:206–209.
17. GageJC, HansonVw, AbbeyK, for the ALTS Group. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006;108:264–268.
18. NamK, ChungS, KwakJ, et al. Random biopsy after colposcopy-directed biopsy improves the diagnosis of cervical intraepithelial neoplasia grade 2 or worse. J Low Genit Tract Dis 2010;14:346–351.
19. ReidR, StanttopeCR, HerschmanBR, et al. Genital warts and cervical cancer. 4. A colposcopic index for differentiating subclinical papillomaviral infection from cervical intraepithelial neoplasia. Am J Obstet Gynecol 1984;149:815–823.
20. ReidR, HerschmanBR, CrumCP, et al. Genital warts and cervical cancer. 5. The tissue basis of colposcopic change. Am J Obstet Gynecol 1984;149:293–303.
21. ReidR, ScaiziP. Genital warts and cervical cancer. 7. An improved colposcopic index for differentiating benign papillomaviral infections from high-grade cervical intraepithelial neoplasia. Am J Obstet Gynecol 1985;153:611–618.
22. RubinM. Follow-up of an abnormal Pap test and colposcopy. In WallisLA (ed.) Textbook of Women’s Health. Philadelphia, PA: Lippincott-Raven, 1998, p. 901.
23. ApgarBS, BrotzmanGL, SpitzerM, et al. Colposcopy: Principles and Practice Textbook and Atlas. Philadelphia, PA: Saunders, 2002.
24. ChaseD, KalouyanM, DisaiaPJ. Colposcopy to evaluate abnormal cervical cytology in 2008. Am J Obstet Gynecol 2009;201:472–480.
25. MousaviAS, FakourR, GillaniMM, et al. A prospective study to evaluate the correlation between Reid colposcopic index impression and biopsy histology. J Low Genit Tract Dis 2007;11:147–150.
26. FerrisDG, LitakerM. Interobserver agreement for colposcopy quality control using digitized colposcopic images during ATLS trial. J Low Genit Tract Dis 2005;9:29–35.
27. FerrisDG, LitakerMSfor the ALTS Group. Prediction of cervical histologic results using an abbreviated Reid colposcopic index during ALTS. Am J Obstet Gynecol 2006;194:704–710.
28. OsterAGNatural History of CIN: a critical review. Int J Gynecol Pathol 1993;12:186–192.
29. KurmanRJ, MalkasianGD, SedlisA, et al. From Papanicolaou to Bethesda: the rationale for a new cervical cytology classification. Obstet Gynecol 1991;77:779–782.
30. ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from randomized trial. JNCI 2000;92:397–402.
31. MoscickiAB, ShiboskiS, BroeringJ, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277–284.
32. SchiffmanM, WetzensenN. From human papillomavirus to cervical cancer. Obstet Gynecol 2010;116:177–185.
33. KiviatN. Natural history of cervical neoplasia: overview and update. Am J Obstet Gynecol 1996;175:1099–1104.
34. CuzickJ, SzarewskiA, TerryG, et al. Human papillomavirus testing in primary cervical screening. Lancet 1995;345:1533–1536.
35. ParkTW, RichartRM, SunXW, WrightTC. Association between human papillomavirus type and clonal status of cervical squamous intraepithelial lesions. JNCI 1996;88:317–318.
36. KoutskyLA, HolmesKK, CritchlowCW, et al. Cohort study of risk of cervical intraepithelial neoplasia grade 2 or 3 associated with cervical papillomavirus infection. N Engl J Med 1992;327:1272–1278.
37. DalySF, DoyleM, EnglishJ, et al. Can the number of cigarettes smoked predict high-grade cervical intraepithelial neoplasia among women with mildly abnormal cervical smears?Am J Obstet Gynecol 1998;179:399–402.
38. BrissonJ, MorinC, FortierM, et al. Risk factors for cervical intraepithelial neoplasia: differences between low and high-grade lesions. Am J Epidemiol 1994;140:700–710.
39. HoGY, KadishAS, BurkRD, et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intraepithelial neoplasia, Int J Cancer 1998;78:281–285.
40. Roteli-MartinsCM, PanettaK, AlvesVA, et al. Cigarette smoking and high-risk HPV DNA as predisposing factors for high-grade cervical intraepithelial neoplasia (CIN) in young Brazilian women. Acta Obstet Gynecol Scand 1998;77:678–682.
41. GiulianoAR, PapenfussM, SchneiderA, et al. Risk factors for high-risk type papillomavirus infection among Mexican-American women. Cancer Epidemiol Biomarkers Prev 1999;8:615–620.
42. IsmailSM, ColcloughAB, DinnenJS, et al. Observer variation in histopathological diagnosis and grading of cervical intraepithelial neoplasia. BMJ 1989;298:707–710.
43. ParakevaidisE, KitchenerHC, MillerID, et al. A population-based study of microinvasive disease of the cervix – a colposcopic and cytologic analysis. Gynecol Oncol 1992;45:9–12.
44. HopmanEH, KenemansP, HelmerhorstTJM. Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature. Obstet Gynecol Surv 1998;53:97–106.
45. LiuWM, ChaoKC, WangKI, et al. Colposcopic assessment in microinvasive carcinoma of the cervix. Chin Med J 1989;43:171–176.
46. YoonessiM, WieckowskaW, MarinielloD, et al. Cervical intraepithelial neoplasia in pregnancy. Int J Gynecol Obstet 1982;20:111–118.
47. LurainJR, GallupDG. Management of abnormal Papanicolaou smears in pregnancy. Obstet Gynecol 1979;53:484–488.
48. NevinJ, SoetersR, DehaeckK, et al. Cervical carcinoma associated with pregnancy. Obstet Gynecol Surv 1995;50:228–239.
49. GreerBE, GoffBA, KohWJ, et al. Cancer in the pregnant patient. In HoskinsWJ, PerezCA, YoungRC (eds.) Principles and Practice of Gynecologic Oncology, 2nd edn. Philadelphia, PA: Lippincott-Raven, 1997, p. 463.
50. WrightTC, MassadSL, DuntonCJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007: 346–355.
51. MassadLS, EinsteinMH, et al. Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013;121:829–846.
52. KaplanKJ, Dainty LA DolinksyB, RoseGS, et al. Prognosis and recurrence risk for patients with cervical squamous intraepithelial lesions diagnosed during pregnancy. Cancer 2004;102:228–232.
53. OstergardDR. The effect of pregnancy on the cervical squamocolumnar junction in patients with abnormal cervical cytology. Am J Obstet Gynecol 1979;134:759–760.
54. HanniganEV, WhitehouseHH, AtkinsonWD, et al. Cone biopsy during pregnancy. Obstet Gynecol 1982;60:450–455.
55. LarssonG, GrunsdellH, GullbergB, et al. Outcome of pregnancy after conization. Acta Obstet Gynecol Scand 1982;61:461–466.
56. KiguchiK, BibboM, HasegawaT, et al. Dysplasia during pregnancy: a cytologic follow-up study. J Reprod Med 1981;26:66–72.
57. YostNP, SantosoJT, McIntireDD, IliyaFA. Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. Obstet Gynecol 1999;93:359–362.
58. KaplanKJ, DaintyLA, DolinskyB, et al. Prognosis and recurrence risk for patients with cervical squamous intraepithelial lesions diagnosed during pregnancy. Cancer 2004;102:228–232.
59. HackerNF, BerekJS, LagasseLD, et al. Carcinoma of the cervix associated with pregnancy. Obstet Gynecol 1982;59:735–746.
60. WinerRL, FengQ, HughesJP, et al. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008;197:279–282.
61. WinerRL, LeeSK, HughesJP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218–226.
62. MoscikiAB, EllenburgJH, VermundSH, et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 2000;154:127–134.
63. ForhanSE, GottliebSL, SternbergMR, et al. Prevalence of sexually transmitted infections among female adolescents aged 14–19 in the United States. Pediatrics 2009;124:1505–1512.
64. MoscickiAB. Impact of HPV infection in adolescent populations. J Adolesc Health 2005;37(Suppl):S3–S9.
65. SaslowD, SolomonD, LawsonHW. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis 2012;16:175–204.
66. Freeman-WangT, WalkerP. Colposcopy in special circumstances: Pregnancy, immunocompromise, including HIV and transplants, adolescence and menopause. Best Pract Res Clin Obstet Gynecol 2011;25:653–665.
67. UNAIDS. UNAIDS Report on Global AIDS Epidemic. New York: UNAIDS, 2010.
68. MaimanM. Management of cervical neoplasia in human immunodeficiency virus infected women. JNCI Monogr 1998;23:43–49.
69. DuerrA, ParamsothyP, JamiesonDJ, et al. HIV Epidemiology Research Study. Effect of HIV infection on atypical squamous cells of undetermined significance. Clin Infect Dis 2006;42:855–861.
70. SunXW, KuhnL, EllerbrockTV, et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997;337:1343–1349.
71. PalefskyJM, MinkoffH, KalishLA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. JNCI 1999;91:226–236.
72. BrancaM, DelfinoA, RossiE, et al. Cervical intraepithelial neoplasia and human papillomavirus related lesions of the genital tract in HIV positive and negative women. Eur J Gynaecol Oncol 1995;16:410–417.
73. PantanowitzL, MichelowP. Review of human immunodeficiency virus and squamous lesions of the uterine cervix. Diagn Cytopath 2010;39:65–72.
74. ChirenjeZM. HIV and cancer of the cervix. Best Pract Res Clin Obstet Gynaecol 2005;19:269–276.
75. MassadLS, AhdiehL, BenningL, et al. Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women’s interagency HIV study. J Acquire Immune Defic Syndr 2001;27:432–442.
76. SchragerLK, FriedlandGH, MaudeD, et al. Cervical and vaginal squamous cell abnormalities in women infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1989;2:570–575.
77. SchaferA, FriedmannW, MielkeM, et al. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 1991;164:593–599.
78. VermundSH, KelleyKF, KleinRS, et al. High risk of human papillomavirus infection and squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am J Obstet Gynecol 1992;165:392–400.
79. MandelbattJS, FahsM, GaribaldiK, et al. Association between HIV infection and cervical neoplasia: implications for clinical care of women at risk for conditions. AIDS 1992;6:173–178.
80. KleinRS, HoGYF, VermundSH, et al. Risk factors for squamous intraepithelial lesions on Pap smear in women at risk for human immunodeficiency virus infection. J Infect Dis 1994;170:1404–1409.
81. MassadLS, FazzariMJ, AnastosK, et al. Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis 2007;11:90–97.
82. FruchterRG, MaimanM, SedlisA, et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996;87:338–344.
83. FoulotH, HeadI, PotardV, CostagliolaD, ChapronC. Surgical management of cervical intraepithelial neoplasia in HIV-infected women. Eur J Obstet Gynecol Reprod Biol 2008;141:153–157.
84. ReimersLL, SotardiS, DanielD, et al. Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women. Gynecol Oncol 2010;119:92–97.
85. HalpertR, FruchterRG, SedlisA, et al. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 1986;68:251–258.
86. PennJ. Cancers in cyclosporine-treated vs. azathioprine treated patients. Transplant Proc 1996;28:876–878.
87. SavaniBN, StrattonP, ShenoyA, et al. Increased risk of cervical dysplasia in long term survivors of allogeneic stem cell transplantation- implications for screening and HPV vaccination. Biol Blood Marrow Transplant 2008;14:1072–1095.
88. KlumbEM, AraujoML Jr., JesusGR, et al. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression?J Clin Rheumatol 2010;16:153–157.
89. SinghH, DemersAA, NugentZ, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case control study. Gastroenterology 2009;136:451–458.
90. US Department of Health and Human Services. Treatment of Opportunistic Infections. Washington, DC: US Department of Health and Human Services, National Institutes of Health, CDC, 2006.
91. WrightTC, Jr., MassadLS, DuntonCJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007;11:201–222.
92. BowerM, CollinsS, CottrillC., et al. AIDS Malignancy Subcomittee. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 2008;9:336–388.
93. HerbstAL, UlfelderH, PoskancerDC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284–878.
94. JefferiesJA, RobboySJ, O’BrienPC, et al. Structural anomalies of the cervix and vagina in women enrolled in the diethylstilbestrol adenosis (DESAD) project. Am J Obstet Gynecol 1984;148:59–66.
95. KatkiHA, SchiffmanM, CastlePE, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 2013;17(Suppl 1):S28–S35.
96. DarraghTM, ColganTJ, CoxJT, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions:background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch of Pathol Lab Med 2012;136:1266–1297.

References

1. KalraMK, MaherMM, TothTL, et al. Strategies for CT radiation dose optimization. Radiology 2004;230:619–628.
2. SilvaAC, LawderHJ, HaraA, KujakJ, PavlicekW. Innovations in CT dose reduction strategy: application of the adaptive statistical iterative reconstruction algorithm. AJR Am J Roentgenol 2010;194:191–199.
3. KuoPH, KanalE, bu-AlfaAK, CowperSE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007;242:647–649.
4. ShellockFG, SpinazziA. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol 2008;191:1129–1139.
5. BalleyguierC, SalaE, DaCT, et al. Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology. Eur Radiol 2011;21:1102–1110.
6. KinkelK, ForstnerR, DanzaFM, et al. Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging. Eur Radiol 2009;19:1565–1574.
7. von SchulthessGK, SteinertHC, HanyTF. Integrated PET/CT: current applications and future directions. Radiology 2006;238:405–422.
8. WahlRL, JaceneH, KasamonY, LodgeMA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122S–150S.
9. MitchellDG, SchonholzL, HilpertPL, et al. Zones of the uterus: discrepancy between US and MR images. Radiology 1990;174:827–831.
10. NishizawaS, InubushiM, OkadaH. Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging 2005;32:549–556.
11. CarringtonBM, HricakH, NuruddinRN, et al. Mullerian duct anomalies: MR imaging evaluation. Radiology 1990;176:715–720.
12. MarkAS, HricakH, HeinrichsLW, et al. Adenomyosis and leiomyoma: differential diagnosis with MR imaging. Radiology 1987;163:527–529.
13. ReinholdC, TafazoliF, MehioA, et al. Uterine adenomyosis: endovaginal US and MR imaging features with histopathologic correlation. Radiographics 1999;19:S147–S160.
14. TamaiK, TogashiK, ItoT, et al. MR imaging findings of adenomyosis: correlation with histopathologic features and diagnostic pitfalls. Radiographics 2005;25:21–40.
15. MuraseE, SiegelmanES, OutwaterEK, Perez-JaffeLA, TureckRW. Uterine leiomyomas: histopathologic features, MR imaging findings, differential diagnosis, and treatment. Radiographics 1999;19:1179–1197.
16. PattaniSJ, KierR, DealR, LuchanskyE. MRI of uterine leiomyosarcoma. Magn Reson Imaging 1995;13:331–333.
17. RhaSE, ByunJY, JungSE, et al. CT and MRI of uterine sarcomas and their mimickers. AJR Am J Roentgenol 2003;181:1369–1374.
18. ManfrediR, MirkP, MarescaG, et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology 2004;231:372–378.
19. SalaE, RockallA, RangarajanD, Kubik-HuchRA. The role of dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging in the female pelvis. Eur J Radiol 2010;76:367–385.
20. HricakH, PowellCB, YuKK, et al. Invasive cervical carcinoma: role of MR imaging in pretreatment work-up: cost minimization and diagnostic efficacy analysis. Radiology 1996;198:403–409.
21. OkamotoY, TanakaYO, NishidaM, et al. MR imaging of the uterine cervix: imaging-pathologic correlation. Radiographics 2003;23:425–445.
22. ReinhardtMJ, Ehritt-BraunC, VogelgesangD, et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 2001;218:776–782.
23. ScheidlerJ, HeuckAF. Imaging of cancer of the cervix. Radiol Clin North Am 2002;40:577–579.
24. SalaE, WakelyS, SeniorE, LomasD. MRI of malignant neoplasms of the uterine corpus and cervix. AJR Am J Roentgenol 2007;188:1577–1587.
25. JeongYY, OutwaterEK, KangHK. Imaging evaluation of ovarian masses. Radiographics 2000;20:1445–1470.
26. SassoneAM, Timor-TritschIE, ArtnerA, WesthoffC, WarrenWB. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991;78:70–76.
27. TimmermanD, ValentinL, BourneTH, et al. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol 2000;16:500–505.
28. LevineD, BrownDL, AndreottiRF, et al. Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology 2010;256:943–954.
29. BaerwaldAR, AdamsGP, PiersonRA. Form and function of the corpus luteum during the human menstrual cycle. Ultrasound Obstet Gynecol 2005;25:498–507.
30. BourneTH, HagstromH, HahlinM, et al. Ultrasound studies of vascular and morphological changes in the human corpus luteum during the menstrual cycle. Fertil Steril 1996;65:753–758.